Rima M. Saliba, PHD

Peer-Reviewed Articles

1. Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B. Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide. Leukemia, 2026. e-Pub 2026. PMID: 41803402.
2. Saliba RM, Niemann M, Srour SA, Greenbaum U, Alzahrani KK, Carmazzi Y, Rondon G, Rezvani K, Daher M, Li D, Ma Q, Tanner MR, Cao K, Shpall EJ, Champlin RE, Spierings E, Zou J. Molecular Disparity of HY Antigen Affects Chronic Graft-Versus-Host Disease and Relapse in Female-to-Male Stem Cell Transplants. Transplant Cell Ther 31(11):903-915, 2025. e-Pub 2025. PMID: 40714365.
3. Pasvolsky O, Shimony S, Saliba RM, Marcoux C, Ledesma C, Rondon G, Tewari P, Ragoonanan D, Short NJ, Jabbour E, Gooptu M, Ho VT, Soiffer RJ, Antin JH, Koreth J, Cutler CS, Paolino JD, Duncan CN, Lehmann LE, DeAngelo DJ, Jain N, Champlin R, Shpall E, Luskin MR, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study. Am J Hematol 101(1):16-25, 2025. e-Pub 2025. PMID: 41051170.
4. Lontos K, Saliba RM, Kanagal-Shamanna R, Ozcan G, Ramdial J, Chen G, Kadia T, Short NJ, Daver NG, Kantarjian H, Marin D, Kebriaei P, Popat U, Champlin R, Shpall E, Oran B. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation. Blood Adv 9(11):2845-2854, 2025. e-Pub 2025. PMID: 39853269.
5. Alkhunaizi, M, Soto-Lanza, F, Leung, CH, Bhan, N, Bashoura, L, Dickey, BF, Sharifi, H, Cheng, GS, Yanik, G, Rondon, G, Saliba, RM, Chen, GL, Al-Atrash, G, Hosing, C, Kebriaei, P, Popat, UR, Shpall, E, Champlin, RE, Li, L, Alousi, AM, Sheshadri, A. Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality. Transplantation and Cellular Therapy 31(4):255.e1-255.e10, 2025. e-Pub 2025. PMID: 39921208.
6. Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, Ahmed S, Yilmaz M, Daver N, Ravandi F, DiNardo C, Short NJ, Kadia T, Al-Atrash G, Daher M, Costa DM, Popat U, Champlin R, Shpall E, Oran B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
7. Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, Hosing C, Kebriaei P, Olson A, Mehta R, Chen G, Qazilbash M, Shpall E, Champlin RC, Saliba RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
8. Rahman ZA, Othman T, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther 30(12):1197-1205, 2024. e-Pub 2024. PMID: 39332807.
9. Saliba RM, Lee SJ, Carpenter PA, Hill GR, Lee CJ, Alousi A, Daher M, Chen G, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus-seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica 109(7):2321-2325, 2024. e-Pub 2024. PMID: 38426274.
10. Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
11. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat U, Oran B, Olson A, Bashir Q, Qazilbash M, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri I, Srour S, Champlin R, Shpall E, Kebriaei P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
12. Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, Shpall EJ, Weisdorf D, Mehta RS. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol 99(1):38-47, 2023. e-Pub 2024. PMID: 37850688.
13. Marinos A, Ramdial J, Khawaja F, Saliba RM, Shigle TL, Alousi AM, Rondon G, Chen J, Ledesma C, Champlin RE, Daher M, Chen G, Marin D, Rezvani K, Shpall EJ, Chemaly RF. Hematopoietic cell transplantation can be safely performed after COVID-19. Bone Marrow Transplant 58(12):1410–1412, 2023. e-Pub 2024. PMID: 37726490.
14. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201(4):e37-e41, 2023. e-Pub 2023. PMID: 36916461.
15. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol, 2023. e-Pub 2017. PMID: 28834808.
16. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2022. PMID: 36470579.
17. Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematologic Stem-Cell Transplant. JCO Oncol Pract 19(3):e417–e427, 2023. e-Pub 2024. PMID: 36626702.
18. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2022. e-Pub 2024. PMID: 36502492.
19. Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A. Risk factors for bronchiolitis obliterans syndrome after initial detection of pulmonary impairment. Transplant Cell Ther 29(3):204.e1–204.e7, 2022. e-Pub 2024. PMID: 36503180.
20. Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplant Cell Ther 28(10):681-693, 2022. e-Pub 2022. PMID: 35853610.
21. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
22. Saliba RM, Srour SA, Greenbaum U, Ma Q, Carmazzi Y, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Li D, Saengboon S, Alousi AM, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol 13:904718, 2022. e-Pub 2022. PMID: 35874659.
23. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2024. PMID: 35662592.
24. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 28(8):500.e1-500.e10, 2022. e-Pub 2024. PMID: 19450756.
25. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.el-395.ell, 2022. e-Pub 2024. PMID: 35513252.
26. Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei P. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant 52(1):20-27, 2022. e-Pub 2016. PMID: 27618682.
27. Yeh JC, Whited LK, Saliba RM, Rondon G, Banchs J, Shpall EJ, Champlin RE, Popat UR. Cardiac Toxicity after Matched Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. Blood Adv 5(24):5599–5607, 2021. e-Pub 2021. PMID: 34592759.
28. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia(36):257–262, 2021. e-Pub 2024. PMID: 34876697.
29. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Graft for Haploidentical HCT with Post Transplantation Cyclophosphamide. Transplant Cell Ther:S2666-6367, 2021. e-Pub 2021. PMID: 34537419.
30. Saliba RM, Greenbaum U, Ma Q, Srour SA, Carmazzi Y, Li L, Oran B, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Partlow D, Li D, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv 5(17):3407-3417, 2021. e-Pub 2021. PMID: 34495313.
31. Alousi AM, Saliba RM. Pre-transplant Transfusion Burden and Transplant Outcomes, Is there a Case for Earlier Transplant?. Transplant Cell Ther 27(8):625-626, 2021. e-Pub 2021. PMID: 34304800.
32. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
33. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2021. e-Pub 2019. PMID: 30763728.
34. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia, 2021. e-Pub 2021. PMID: 34135465.
35. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
36. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late no relapse mortality. Bone Marrow Transplant 56:2005-2012, 2021. e-Pub 2021. PMID: 33846563.
37. Shah MV, Saliba RM, Verma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
38. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
39. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract GraftVersus-Host Disease. Transplantation and Cellular Therapy 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
40. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
41. Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
42. Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106(1):269-274, 2021. e-Pub 2021. PMID: 32107328.
43. Abudayyeh A, Lin H, Mamlouk O, Abdelrahim M, Saliba R, Rondon G, Martinez CS, Delgado R, Page V, Rajasekaran A, Sanders PW, Qazilbash M. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma 61(13):3101-3111, 2020. e-Pub 2020. PMID: 32723196.
44. Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, Mehta RS, Popat UR, Hosing CM, Rondon G, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant 56:745-748, 2020. e-Pub 2020.
45. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):74-81, 2020. e-Pub 2020. PMID: 32604096.
46. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
47. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour E, Mehta R, Popat U, Ravandi F, Alousi A, Kadia T, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplant cyclophosphamide improves transplant outcomes in AML/MDS patients treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
48. Varma A, Rondon G, Srour SA, Chen J, Ledesma C, Champlin RE, Ciurea SO, Saliba RM. Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. Biology Blood Marrow Transplant 26(5):1013-1020, 2020. e-Pub 2020. PMID: 32045652.
49. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
50. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
51. Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem-Cell Transplant Outcomes. Biol Blood Marrow Transplant 23(12):2166-2171, 2018. e-Pub 2017. PMID: 28844946.
52. Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 54(4):601–606, 2018. e-Pub 2024. PMID: 30337700.
53. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2024. PMID: 30016656.
54. Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Ramos Perez JM, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2024. PMID: 29769261.
55. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
56. Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9:2444, 2018. e-Pub 2018. PMID: 30405633.
57. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2017. e-Pub 2024. PMID: 29269797.
58. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. In-patient versus out-patient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol, 2017. e-Pub 2024. PMID: 28895206.
59. Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2017. e-Pub 2024. PMID: 28918304.
60. Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR. Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant 23(7):1059-1063, 2017. e-Pub 2017. PMID: 28389254.
61. Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2024. PMID: 28351938.
62. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2024. PMID: 28506845.
63. Saliba RM, Sarantopoulos S, Kitko CL, Pawarode A, Goldstein SC, Magenau J, Alousi AM, Churay T, Justman H, Paczesny S, Reddy P, Couriel DR. B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. Bone Marrow Transplant 52(7):1010-1015, 2017. e-Pub 2024. PMID: 28481353.
64. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2024. PMID: 28324640.
65. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2024. PMID: 28295190.
66. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2024. PMID: 28052408.
67. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant 24(7):1514-1520, 2017. e-Pub 2024. PMID: 29448058.
68. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion 57(4):1052-1057, 2017. e-Pub 2024. PMID: 28185276.
69. Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 23(4):581-587, 2017. e-Pub 2024. PMID: 28063964.
70. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 91(10):E442-7, 2016. e-Pub 2016. PMID: 27420405.
71. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173(3):444-55, 2016. e-Pub 2016. PMID: 26947769.
72. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 22(7):1333-1337, 2016. e-Pub 2024. PMID: 27064056.
73. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant, 2016. e-Pub 2024. PMID: 26950376.
74. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
75. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant 21(11):1948-54, 2015. e-Pub 2015. PMID: 26183077.
76. Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MH. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplant 51(2):307–309, 2015. e-Pub 2024. PMID: 26479980.
77. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
78. Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1413-7, 2015. e-Pub 2015. PMID: 25842049.
79. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant 21(7):1284-90, 2015. e-Pub 2015. PMID: 25708219.
80. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
81. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. Biol Blood Marrow Transplant 21(5):855-9, 2015. e-Pub 2015. PMID: 25652691.
82. Hosing C, Saliba RM, Hamerschlak N, Kutner JM, Sakashita AM, Kondo AT, Rodrigues M, Fernande JF, Chiattone A, Chiattone VC, Barros JC, Chiattone CS, Chiattone R, Popat U, Qazilbash M, Tang XW, Wu D, Majilis A, de Lima M, Anguita T. Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers. Transfusion 54(4):1081-7, 2014. e-Pub 2014. PMID: 24118027.
83. Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R, Ferguson J, Westmoreland M, Rondon G, Kebriaei P. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract 20(4):257-262, 2013. e-Pub 2024. PMID: 24022408.
84. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer 119(18):3318-3325, 2013. e-Pub 2024. PMID: 23775587.
85. Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB. Ex Vivo T Cell Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission. Biol Blood Marrow Transplant 19(6):898-903, 2013. e-Pub 2013. PMID: 23467126.
86. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. Biol Blood Marrow Transplant 19(8):1227-1232, 2013. e-Pub 2024. PMID: 23733001.
87. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-1064, 2013. e-Pub 2024. PMID: 23644077.
88. Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. Blood 121(13):2567-2573, 2013. e-Pub 2024. PMID: 23361908.
89. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
90. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-1844, 2012. e-Pub 2012. PMID: 22796535.
91. Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma following Non-myeloablative Allogeneic Stem Cell Transplantation. Leuk Lymphoma 53(8):1525-1529, 2012. e-Pub 2012. PMID: 22242817.
92. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma 53(6):1239-1241, 2012. e-Pub 2012. PMID: 22132837.
93. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-6378, 2012. e-Pub 2012. PMID: 22586182.
94. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-6, 2012. e-Pub 2012. PMID: 21988645.
95. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499-502, 2012. e-Pub 2012. PMID: 21859247.
96. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2012. e-Pub 2012. PMID: 21423123.
97. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, Champlin RE, Alousi AM. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 47(1):125-31, 2012. e-Pub 2012. PMID: 21383686.
98. Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 2011. e-Pub 2011. PMID: 21684343.
99. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
100. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth Through Eighth Decades of Life. Biol Blood Marrow Transplant 17(10):1490-6, 2011. e-Pub 2011. PMID: 21338705.
101. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biol Blood Marrow Transplant 18(4):584-592, 2011. e-Pub 2024. PMID: 21867666.
102. Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Cano P, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one-human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant 17(6):923-9, 2011. e-Pub 2011. PMID: 20969970.
103. Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 46(4):510-5, 2011. e-Pub 2011. PMID: 20581887.
104. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011(601953):8 pages, 2011. e-Pub 2011. PMID: 22110505.
105. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 2010. e-Pub 2010. PMID: 20178853.
106. Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, Han XY, Tarrand J, Ribeiro R, Gulbis A, Shpall EJ, Jones R, Popat U, Walker JA, Petropoulos D, Chiattone A, Stewart J, El-Zimaity M, Anderlini P, Giralt S, Champlin RE, de Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 95(7):1183-1190, 2010. e-Pub 2010. PMID: 20410183.
107. Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16(5):686-94, 2010. e-Pub 2010. PMID: 20056165.
108. Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 16(4):555-9, 2010. e-Pub 2010. PMID: 20005966.
109. Efebera Y, Thandi R, Saliba R, Popat U, de Lima M, Alousi A, Hosing C, Rondon G, Champlin R, Giralt S. The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications. The Internet Journal of Hematology 7(1), 2010. e-Pub 2010.
110. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15(12):1555-62, 2009. e-Pub 2009. PMID: 19896079.
111. Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, De Lima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant 15(10):1265-70, 2009. e-Pub 2009. PMID: 19747634.
112. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 2009. e-Pub 2009. PMID: 19660722.
113. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, Lima MD, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-436, 2009. e-Pub 2024. PMID: 19668237.
114. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 2009. e-Pub 2009. PMID: 19539212.
115. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
116. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43(9):685-92, 2009. e-Pub 2009. PMID: 19011667.
117. Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 94(2):249-57, 2009. e-Pub 2009. PMID: 19144658.
118. Efebera YA, Thandi RS, Saliba RM, Popat U, De Lima M, Alousi A, Hosing C, Rondon G, Champlin R, Giralt S. The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. Internet J Hematol 7(1), 2009. e-Pub 2009. PMID: 25356072.
119. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. e-Pub 2008. PMID: 19041063.
120. Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 2008. e-Pub 2008. PMID: 18640568.
121. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol, 2008. e-Pub 2008. PMID: 18564354.
122. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 2008. e-Pub 2008. PMID: 18411419.
123. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19(6):1166-71, 2008. e-Pub 2008. PMID: 18272911.
124. Campagnaro E, Saliba R, Giralt S, Roden L, Mendoza F, Aleman A, Cleeland C, Weber D, Brown J, Anderson KO. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer 112(7):1617-24, 2008. e-Pub 2008. PMID: 18260091.
125. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257-64, 2008. e-Pub 2008. PMID: 18223284.
126. Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, de Lima M, Lichtiger B. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 40(5):461-4, 2007. e-Pub 2007. PMID: 17589530.
127. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
128. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 2007. e-Pub 2007. PMID: 17530009.
129. Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 13(5):543-9, 2007. e-Pub 2007. PMID: 17448913.
130. Khouri IF, Saliba RM, Admirand J, O'Brien S, Lee MS, Korbling M, Samuels BI, Giralt S, Lima de M, Keating MJ, Champlin RE, Bueso-Ramos C. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137(4):355-63, 2007. e-Pub 2007. PMID: 17456058.
131. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 2007. e-Pub 2007. PMID: 17382251.
132. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 109(7):2751-8, 2007. e-Pub 2007. PMID: 17138825.
133. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. e-Pub 2007. PMID: 17262062.
134. Körbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 46(10):1795-802, 2006. e-Pub 2006. PMID: 17002637.
135. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38(3):203-9, 2006. e-Pub 2006. PMID: 16799614.
136. Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt S. Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 38(4):299-303, 2006. e-Pub 2006. PMID: 16819437.
137. Hosing C, Saliba RM, Körbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato ML. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47(7):1290-4, 2006. e-Pub 2006. PMID: 16923559.
138. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47(7):1360-4, 2006. e-Pub 2006. PMID: 16923569.
139. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ, Lee SJ. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 12(5):491-505, 2006. e-Pub 2006. PMID: 16635784.
140. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107(8):3074-80, 2006. e-Pub 2006. PMID: 16368882.
141. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106(5):1084-9, 2006. e-Pub 2006. PMID: 16456814.
142. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 12(1 Suppl 2):37-40, 2006. e-Pub 2006. PMID: 16399600.
143. Cheng YC, Saliba RM, Rondón G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica 90(12):1725-6, 2005. e-Pub 2005. PMID: 16330461.
144. Couriel DR, Saliba R, Escalón MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130(3):409-17, 2005. e-Pub 2005. PMID: 16042691.
145. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 36(2):157-62, 2005. e-Pub 2005. PMID: 15937511.
146. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943-51, 2005. e-Pub 2005. PMID: 15806128.
147. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23(10):2240-7, 2005. e-Pub 2005. PMID: 15800314.
148. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104(3):649-54, 2004. e-Pub 2004. PMID: 15069017.
149. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-24, 2004. e-Pub 2004. PMID: 15122311.
150. Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22(12):2419-23, 2004. e-Pub 2004. PMID: 15197204.
151. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33(10):1015-23, 2004. e-Pub 2004. PMID: 15048145.
152. Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S, Onida F, Beran M, Champlin RE, de Lima M. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 33(10):1005-9, 2004. e-Pub 2004. PMID: 15048141.
153. Khouri IF, Albitar M, Saliba RM, Ippoliti C, Ma YC, Keating MJ, Champlin RE. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 33(8):833-7, 2004. e-Pub 2004. PMID: 14755312.
154. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10(3):178-85, 2004. e-Pub 2004. PMID: 14993883.
155. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 103(3):1140-6, 2004. e-Pub 2004. PMID: 12907445.
156. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32(1):28-35, 2004. e-Pub 2004. PMID: 14725898.
157. El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel D, Giralt S, Khouri I, Ippoliti C, Champlin R, De Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood 103(12):4674-4680, 2004. e-Pub 2004.
158. Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 98(12):2630-5, 2003. e-Pub 2003. PMID: 14669282.
159. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407-12, 2003. e-Pub 2003. PMID: 14645431.
160. Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NT. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 31(12):1157-63, 2003. e-Pub 2003. PMID: 12796796.
161. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 14(5):737-44, 2003. e-Pub 2003. PMID: 12702528.
162. Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4(3):217-21, 2002. e-Pub 2002. PMID: 12194718.
163. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98(13):3595-9, 2001. e-Pub 2001. PMID: 11739162.
164. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, Huh YO, Giralt S, Braunschweig I, van Besien K, Champlin R. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98(6):1695-700, 2001. e-Pub 2001. PMID: 11535499.
165. Saliba RM, Annegers FJ, Waller DK, Tyson JE, Mizrahi EM. Risk factors for neonatal seizures: a population-based study, Harris County, Texas, 1992-1994. Am J Epidemiol 154(1):14-20, 2001. e-Pub 2001. PMID: 11427400.
166. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant 6(2A):190-7, 2000. e-Pub 2000. PMID: 10816027.
167. Saliba RM, Annegers JF, Waller DK, Tyson JE, Mizrahi EM. Incidence of neonatal seizures in Harris County, Texas, 1992-1994. Am J Epidemiol 150(7):763-9, 1999. e-Pub 1999. PMID: 10512430.
168. Gajewski JL, Nimer S, Saliba RM, Thomas M, Przepiorka D, Giralt S, von Besien K, Mehra R, Andersson B, Chan KW, Ippoliti C, Warkinten D, Feigs S, Territo M, Schiller G, Lebkowski J, Moseley AM, Lloyd K, von Hoeff M, Okarma T, Champlin R. Long-term outcome of a phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients. Cytotherapy 1(5):401-7, 1999. e-Pub 1999. PMID: 20426540.
169. Gajewski JL, Nimer S, Saliba RM, Thomas M, Przepiorka D, Giralt S, von Besien K, Mehra R, Andersson B, Chan KW, Ippoliti C, Warkinten D, Feig S, Territo M, Schiller G, Lebkowski L, Moseley AM, Lloyd K, von Hoeff M, Okarma T, and Champlin R. Long term outcome of partial T-cell depletion by panning CD-5/CD8 (+) T-cells in one antigen mismatched related donor and matched unrelated donor. Cytopherapy:401-405, 1999. e-Pub 1999.

Review Articles

1. Ghelani D, Saliba R, Lima M. Secondary malignancies after hematopoietic stem cell transplantation. Crit Rev Oncol Hematol 56(1):115-26, 2005. e-Pub 2005. PMID: 15979325.

Abstracts

1. Hosing CM, Saliba RM, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE, Andersson BS, Shpall EJ, Popat UR. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. Transplantation and Cellular Therapy 31(2,Supplement):S182, 2025. e-Pub 2025.
2. Smallbone P, Cao K, Saliba RM, Alvarez M, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Ramdial JL, Champlin RE, Shpall EJ, Oran B. HLA-DBP1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy 31(2,Supplement):S337, 2025. e-Pub 2025.
3. Srour SA, Saliba RM, Ramdial JL, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen GL, Qazilbash MH, Kebriaei P, Hosing CM, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat UR. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. Transplant and Cellular Therapy 31(2,Supplement):S63, 2025. e-Pub 2025.
4. Rafaeli N, Saliba RM, Senapati J, Daver N, Smallbone P, Kebriaei P, Marin D, Popat U, Kadia TM, Ravandi F, Chen G, Champlin RE, Shpall EJ, Oran B. Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy. Blood 144(Supplement 1):2191, 2024. e-Pub 2024.
5. Smallbone P, Cao K, Saliba RM, Alvarez M, Fingrut WB, Aljawai Y, Olson AL, Alousi AM, Chen G, Ramdial J, Champlin RE, Shpall EJ, Oran B. HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide. Blood 144(Supplement 1):4937, 2024. e-Pub 2024.
6. Saliba RM, Aljawai YM, Alousi AM, Oran B, Popat U, Champlin RE, Shpall EJ. Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide. Blood 144(Supplement 1):4890, 2024. e-Pub 2024.
7. Aljawai YM, Saliba RM, Chen G, Oran B, Fingrut WB, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Marin D, Olson AL, Popat U, Qazilbash MH, Ramdial J, Rondon G, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors. Blood 144(Supplement 1):7442, 2024. e-Pub 2024.
8. Srour SA, Saliba RM, Ramdial J, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen G, Qazilbash MH, Kebriaei P, Hosing C, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat U. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. Blood 144(Supplement 1):3514, 2024. e-Pub 2024.
9. Connors JS, Saliba RM, Ledesma C, Tewari P, Kebriaei P. Single Center Evaluation of Patients with Therapy and Prior-Malignancy Related Acute Lymphoblastic Leukemia and the Use of Hematopoietic Stem Cell Transplants. Transplantation and Cellular Therapy 30(2, Supplement):S115, 2024. e-Pub 2024.
10. Pasvolsky O, Shimony S, Saliba RM, Ledesma C, Rondon G, Tewari P, Ragoonanan D, Short NJ, Jabbour E, Gooptu M, Ho VT, Soiffer RJ, Antin J, Koreth J, Cutler C, Paolino J, Duncan C, Lehmann LE, DeAngelo DJ, Kantarjian HM, Champlin RE, Shpall EJ, Luskin MR, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study. Blood 142(Supplement 1), 2023. e-Pub 2023.
11. Saliba RM, Lee SJ, Carpenter PA, Lee CJ, Hill GR, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. MMF Is Associated with Worse OS in CMV Seropositive AML Patients Undergoing MUD HCT with Calcineurin-Inhibitor-Based Gvhd Prophylaxis. Blood 142(Supplement 1), 2023. e-Pub 2023.
12. Velarde AM, Saliba RM, Ledesma C, Shpall EJ, Qazilbash MH, Popat UR, Bashir Q, Nieto Y, Marin D, Oran B, Olson AL, Srour SA, Alousi A, Ramdial J, Kebriaei P, Ferrajoli A, Wierda WG, Champlin RE, Hosing C. Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis. Blood 142(Supplement 1), 2023. e-Pub 2023.
13. Rahman ZA, Koller PB, Othman T, Saliba RM, Moreno Vanegas YA, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb H, Kantarjian HM, Greipp P, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL). Blood 142(Supplement 1), 2023. e-Pub 2023.
14. Saliba RM, Marcoux C, Alousi A, Rondon G, Chen J, Daher M, MD, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant. Blood 142(Supplement 1), 2023. e-Pub 2023.
15. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood 142(Supplement 1), 2023. e-Pub 2023.
16. Pasvolsky O, Shimony S, Saliba RM, Ledesma C, Rondon G, Tewari P, Ragoonanan D, Short NJ, Jabbour E, Gooptu M, Ho VT, Soiffer RJ, Antin J, Koreth J, Cutler C, Paolino J, Duncan C, Lehmann LE, DeAngelo DJ, Kantarjian HM, Champlin RE, Shpall EJ, Luskin MR, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study. Blood 142(Supplement 1):4979, 2023. e-Pub 2023.
17. Velarde AM, Saliba RM, Ledesma C, Shpall EJ, Qazilbash MH, Popat UR, Bashir Q, Nieto Y, Marin D, Oran B, Olson AL, Srour SA, Alousi A, Ramdial J, Kebriaei P, Ferrajoli A, Wierda WG, Champlin RE, Hosing C. Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis. Blood 142(Supplement 1):7086, 2023. e-Pub 2023.
18. Rahman ZA, Koller PB, Othman T, Saliba RM, Moreno Vanegas YA, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb H, Kantarjian HM, Greipp P, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL). Blood 142(Supplement 1):656, 2023. e-Pub 2023.
19. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood 142(Supplement 1):4920, 2023. e-Pub 2023.
20. Saliba RM, Marcoux C, Alousi A, Rondon G, Chen J, May Daher MD, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant. Blood 142(Supplement 1):2188, 2023. e-Pub 2023.
21. Saliba RM, Lee SJ, Carpenter PA, Lee CJ, Hill GR, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. MMF Is Associated with Worse OS in CMV Seropositive AML Patients Undergoing MUD HCT with Calcineurin-Inhibitor-Based Gvhd Prophylaxis. Blood 142(Supplement 1):236, 2023. e-Pub 2023.
22. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. 540 - Impact of Gender on Outcomes of Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. Transplantation and Cellular Therapy 29(2, Supplement):S404-S405, 2023. e-Pub 2023.
23. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Chen J, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Kantarjian H, Andersson BS, Champlin RE, Shpall EJ. 212 - Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation. Transplantation and Cellular Therapy 29(2, Supplement):S164-S165, 2023. e-Pub 2023.
24. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Gulbis AM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Shigle TL, Srour SA, Rezvani K, Qazilbash MH, Andersson BS, Shpall EJ, Champlin RE. 215 - Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation. Transplantation and Cellular Therapy 29(2, Supplement):S167, 2023. e-Pub 2023.
25. Marinos A, Ramdial JL, Saliba RM, Khawaja F, Alousi AM, Rondon G, Chen J, Ledesma C, Chemaly RF, Champlin RE, Marin D, Daher M, Rezvani K, Shpall EJ. 449 - Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection. Transplantation and Cellular Therapy 29(2, Supplement):S339-S340, 2023. e-Pub 2023.
26. Mehta RS, MD, Saliba RM, PhD, Alousi AM, MD, Alatrash G, PhD, DO, Bashir Q, MD, Kebriaei P, MD, Khouri IF, MD, Nieto Y, MD, Oran B, MD, MS, Popat UR, MD, Qazilbash MH, MD, Ramdial JL, MD, Rondon G, MD, Srour SA, MD, MS, Rezvani K, MD, Champlin RE, MD, Shpall EJ, MD, Cao K, MS, MD. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. ASH 2022, 2022. e-Pub 2022.
27. Mehta RS, MD, Saliba RM, PhD, Alousi AM, MD, Alatrash G, PhD, DO, Bashir Q, MD, Hosing C, MD, Kebriaei P, MD, Khouri IF, MD, Nieto Y, MD, Oran B, MD, MS, Popat UR, MD, Qazilbash MH, MD, Ramdial JL, MD, Rondon G, MD, Srour SA, MD, MS, Rezvani K, MD, Champlin RE, MD, Shpall EJ, MD, Cao K, MS, MD. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. ASH 2022, 2022. e-Pub 2022.
28. Yeh J, PharmD, Saliba RM, PhD, Wang C, PharmD, Fang Z, PharmD, Figgins B, PharmD, Ahmed S, MD, Yilmaz M, MD, Daver N, MD, Mehta RS, MD, Alatrash G, PhD, DO, Marin D, MD, Popat UR, MD, Champlin RE, MD, Shpall EJ, MD, Oran B, MD, MS. Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia. ASH 2022, 2022. e-Pub 2022.
29. Mehta RS, MD, Saliba RM, PhD, Alousi AM, MD, Alatrash G, PhD, DO, Bashir Q, MD, Hosing C, MD, Kebriaei P, MD, Khouri IF, MD, Nieto Y, MD, Oran B, MD, MS, Popat UR, MD, Qazilbash MH, MD, Ramdial JL, MD, Rondon G, MD, Srour SA, MD, MS, Rezvani K, MD, Champlin RE, MD, Shpall EJ, MD, Cao K, MS, MD. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. ASH 2022, 2022. e-Pub 2022.
30. Pasvolsky O, MD, Saliba RM, PhD, Ledesma C, Popat UR, MD, Alousi AM, MD, Olson AL, MD, Oran B, MD, MSc, Hosing C, MD, Bashir Q, MD, Qazilbash MH, MD, Short N, MD, Ravandi F, MD, Champlin RE, MD, Shpall EJ, MD, Kebriaei P, MD. Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond. ASH 2022, 2022. e-Pub 2022.
31. Saliba RM, Ma Q, Srour SA, Rondon G, Shpall EJ, Cao K, Champlin RE, Zou J. 411 - Sirpα Mismatch Impacts Outcomes of Allogeneic Stem Cell Transplantation from HLA-Matched Related Donor for Treatment of Lymphoid Malignancies. https://doi.org/10.1016/S2666-6367(22)00571-1 28(3, Supplement):S318-S319, 2022. e-Pub 2022.
32. Saliba RM, PhD, Ma Q, PhD, Srour SA, Rondon G, MD, Shpall EJ, MD, Cao K, MS, MD D, Champlin RE, MD, Zou J, MD, PhD. Sirpα Mismatch Impacts Outcomes of Allogeneic Stem Cell Transplantation from HLA-Matched Related Donor for Treatment of Lymphoid Malignancies. Transplantation and Cellular Therapy 28(3):S318-S319, 2022. e-Pub 2022.
33. Saliba RM, PhD, Greenbaum U, MD, Ma Q, PhD, Srour SA, Rondon G, MD, Shpall EJ, MD, Cao K, MS, MD, Champlin RE, MD, Zou J, MD, PhD. Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. ASH 2021, 2021. e-Pub 2021.
34. Ramdial JL, MD, Saliba RM, PhD, Alousi AM, MD, Rondon G, MD, Chen J, Ledesma C, Shpall EJ, MD, Chemaly R, MD, PhD, Champlin RE, MD. Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections. ASH 2021, 2021. e-Pub 2021.
35. Mehta S, MD, MPH, MS, Saliba RM, PhD, Jan A, Shigle TL, PharmD, Wang E, Rondon G, Nieto Y, MD, Ciurea S, MD, Oran B, MD, MS, Im JS, Olson AL, Marin D, Qazilbash MH, MD, Khouri IF, MD, Anderlini P, Rezvani K, MD, PhD, Popat UR, MD, Kebriaei P, MD, Shpall EJ, MD, Champlin RE, MD, Alousi AM, MD. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. ASH 2020 136(1):39-40, 2020. e-Pub 2020.
36. Greenbaum U, MD, Strati P, MD, Saliba RM, PhD, Torres J, Rondon G, Nieto Y, MD, Hosing C, MD, Srour SA, MD, MS, Westin J, MD, Fayad L, Lee HJ, MD, Iyer SP, MD, Nastoupil LJ, MD, Parmar S, MD, MSCI, Rodriguez MA, MD, Samaniego F, MD, Steiner RE, MD, Wang M, MD, Pinnix CC, MD, PhD, Flowers C, MD, MS, Tummala S, MD, Ramdial J, MD, Yalniz FF, Hawkins M, Rezvani K, MD, PhD, Champlin RE, MD, Shpall EJ, MD, Neelapu SS, MD, Kebriaei P, MD, Ahmed S, MD. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). ASH 2020 136:17-18, 2020. e-Pub 2020.
37. Guo A, Hill L, Rondon G, Champlin RE, Alousi AM, Saliba RM. Systemic Corticosteroid Therapy is Unlikely to be the Primary Cause of Hyperglycemia following Treatment of Acute Graft-versus-host Disease. EBMT 2020, 2020. e-Pub 2020.
38. Uday R Popat MD, Saliba PhD RM, Nicholas Szewczyk RN, MSN, ANP-C, PA-C RL, Zandra Rivera RN, MS, ANP-BC, PharmD JF, Rhodora C Fontillas BS, DPT, Latoya Adekoya BA, MOT, Haley Gale MHS, RD, Courtland A Lee BS, MA, LihuiCaoMSN, RN, RN-BC, CNL, BMTCN, BarelasSullivanMSN H, RN, CNL, OCN, JulianneChenBS, GabrielaRondonMD, BeckyMcMullinBSN, RN, Shigle PharmD TL, BCPS, BCOP, PharmD LK, PharmD AM, Richard EChamplin MD. Enhanced Recovery Program in Older Patients Undergoing Allogeneic Stem Cell Transplantation (ER-SCT): First Year Outcomes. TCT 2020 26(3):S49-S50, 2020. e-Pub 2020.
39. Popat U, MD, Saliba RM, PhD, Rohtesh S Mehta MD, MPH, MS, Amanda Olson MD, Julianne Chen BS, Christina Ganesh BSN, RN, Glenda Woodworth BSN, RN, Becky McMullin BSN, RN, Amin M Alousi MD, Paolo Anderlini MD, Gheath Alatrash MD, Qaiser Bashir MD, Stefan O Ciuera MD, Chitra Hosing MD, Jin Seon Im MD, PhD, Partow Kebriaei MD, Issa F Khouri MD, David Marin MD, Richard E Champlin MD. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. TCT 2020 26(3):S125, 2020. e-Pub 2020.
40. PharmD JY, Whited PharmD LK, Saliba PhD RM, Gabriela Rondon MD, Uday R Popat MD. Cardiac Toxicities after HLA-Matched Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Post-Transplant Cyclophosphamide (PTCy) Is Not Associated with Higher Incidence of Cardiotoxicity. TCT 2020 26(3):S393-S394, 2020. e-Pub 2020.
41. PhD RM, MuktaArora MD, MS, Stephen RSpellman MBS, Michael THemmer MS, PhD T, Amin MAlousi MD, Joseph APidala MD, PhD, MadanJagasia MD, LMacMillanMD M, MSc, FRCPC, Mary MHorowitz MD, MS, JeffreySchriber MD, Richard EChamplin MD, Stefan OCiurea MD. Acute Graft-Versus-Host Disease Is Less Severe and Associated with Lower Non-Relapse Mortality after Haploidentical Transplantation with Post-Cyclophosphamide Prophylaxis. TCT 2020 26(3):S26-S27, 2020. e-Pub 2020.
42. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. EHA 2019 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
43. Popat U, MD, Saliba RM, PhD, Mehta RS, MD, Olson AL, MD, Chen J, Ganesh C, BSN, RN, Rondon G, MD, Woodworth G, BSN, OCN, RN, McMullin B, Alousi AM, MD, Anderlini P, Alatrash G, DO, PhD, Bashir Q, MBBS, Ciurea SO, MD, Hosing C, MD, Im JS, PhD MD, Kebriaei P, MD, Khouri IF, MD, Marin D, MD, Nieto Y, PhD MD, Oran B, MDMS, Saini N, MD, Srour S, Rezvani K, PhD MD, Qazilbash MH, MD, Molldrem JJ, Shpall EJ, MD, Andersson BS, PhD MD, Champlin RE, MD. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. ASH 2019 134(1):3296, 2019. e-Pub 2019.
44. Yalniz FF, Saliba RM, PhD, Yucel OK, Garcia-Manero G, MD, Ramdial J, MD, Popat U, MD, Ciurea SO, MD, Kebriaei P, MD, Alousi AM, MD, Alatrash G, DO, PhD, Bashir Q, MBBS, Hosing C, MD, Marin D, MD, Mehta R, MD, Olson AL, MD, Rezvani K, PhD MD, Shpall EJ, MD, Rondon G, MD, Champlin RE, MD, Oran B, MD. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. ASH 2019 134(1):512, 2019. e-Pub 2019.
45. Koller P, Saliba RM, PhD, Ledesma C, Rondon G, MD, Popat U, MD, Alousi AM, MD, Mehta RS, MD, Oran B, MDMS, Olson AL, MD, Hosing C, MD, Qazilbash MH, MD, Khouri IF, MD, Ciurea SO, MD, Shpall EJ, MD, Jorgensen JL, PhD MD, Wang SA, MD, Jain N, MD, Jabbour E, MD, Kantarjian HM, MD, Champlin RE, Konopleva MY, PhD MD, Kebriaei P, MD. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. ASH 2019 134(1):4598, 2019. e-Pub 2019.
46. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 134(Supplement_1):47, 2019. e-Pub 2019. PMID: 31723997.
47. Abudayyeh A, Abdelrahim M, Lin HY, Saliba R, Martinez C, Delgado R, Page VD, Sanders PW, Qazilbash MH. Impact of autologous stem cell transplant in myeloma patients on renal function and overall survival. ASCO 2019, 2019. e-Pub 2019.
48. Saliba, R, Alousi, A, Andersson, B, Chen, J, Rohtesh, M, Molldrem, J, Champlin, R, Popat, U. Higher Pre-Transplant IL-2 Levels Correlate with Higher Incidence of Acute Graft-Versus-Host Disease. TCT 2019 25(3):S245, 2019. e-Pub 2019.
49. Neeraj Saini MD, Saliba PhD RM, Romil D Patel MD, Mustafa Nooruldeen Abdulrazzaq MD, Chitra M Hosing MD, Amin M Alousi MD, Paolo Anderlini MD, Uday R Popat MD, Muzaffar H Qazilbash MD, EJ J Shpall MD, Partow Kebriaei MD, Loretta J Nastoupil MD, Jason R Westin MD, MS, Gabriela Rondon MD, Borje S Andersson MD, PhD, Richard E Champlin MD, Tariq R Muzzafar MD, Yago Nieto MD, PhD, Sairah Ahmed MD. Does Cell of Origin Classification Impact Outcomes in Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplant. TCT 2019 25(3):S394-S395, 2019. e-Pub 2019.
50. Ciurea, S, Saliba, R, Soebbing, D, Rondon, G, Cao, K, Olson, A, Bashir, Q, Shpall, EJ, Lee, D, Champlin, R. LBA11 - Outcomes with High-Doses of Vivo Expanded NK Cells after Haploidentical Stem Cell Transplantation (haploSCT). TCT 2019, 2019. e-Pub 2019.
51. Saliba RM, PhD, Rondon G, MD, Chen J, BS, Ledesma C, BS, Champlin RE, MD, Ciurea SO, MD. Endothelial Activation and Stress Index (EASIX) Is Associated with Fluid Overload and Survival in Recipients of Allogeneic Stem Cell Transplantation. TCT 2019 26(5):1013-1020, 2019. e-Pub 2019.
52. Daher M, Cao K, MS, MD, Basar R, MD, Marin D, MD, Sekine T, Rondon PG, MD, Zhao W, MS, Smith NT, MS, Wang Q, BS, Li L, MD, Saliba RM, PhD, Kiran Pingali SR, MD, Popat U, MD, Hosing C, MD, Olson AL, MD, Oran B, MD, MS, Mehta RS, MD, MPH, MS, Champlin RE, MD, Shpall EJ, MD, Rezvani K, MD, PhD. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation. ASH 2018, 2018. e-Pub 2018.
53. Dos Santos DMC, Saliba RM, PhD, Patel R, BA, Bashir Q, MBBS, Hosing C, MD, Kebriaei P, MD, Khouri IF, Nieto Y, MD, PhD, Popat U, MD, Lee HC, MD, Manasanch EE, MD, Patel KK, MD, MSc, Thomas SK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. ASH 2018, 2018. e-Pub 2018.
54. Oran B, MD, MS, Garcia-Manero G, MD, Saliba RM, PhD, Alatrash G, DO, PhD, Jabbour EJ, MD, Popat U, MD, Ravandi F, MBBS, Kadia TM, MD, Cortes JE, MD, Alousi AM, MD, Konopleva MY, MD, PhD, DiNardo CD, MD, MSc, Rezvani K, MD, PhD, Alfayez M, MD, Shpall EJ, MD, Sharma P, MD, PhD, Champlin RE, MD, Kantarjian HM, MD, Daver NG, MD. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. ASH 2018, 2018. e-Pub 2018.
55. Saini NY, MD, Saliba RM, PhD, Rondon G, MD, Maadani F, Popat U, MD, Oran B, MD, MS, Hosing C, MD, Bashir Q, MBBS, Olson AL, MD, Nieto Y, MD, PhD, Alousi AM, MD, Kebriaei P, MD, Srour SA, MD, Mehta RS, MD, MPH, MS, Anderlini P, MD, Shpall EJ, MD, Qazilbash MH, MD, Khouri IF, Fayad LE, Lee HJ, MD, Fowler NH, MD, Parmar S, MBBS, Westin JR, MD, Hagemeister F, MD, Champlin RE, MD, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. ASH 2018, 2018. e-Pub 2018.
56. Shah MV, Saliba RM, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Ahmed S, Alousi AM, Mehta RS, Pemmaraju N, Verstovsek S, Popat UR. Transplant Outcomes for Patients with Secondary Acute Myeloid Leukemia (AML) Arising From Myeloproliferative Neoplasms (MPN). ASBMT 2018 24(3):S322-S323, 2018. e-Pub 2018.
57. Ciurea SO, Saliba RM, PhD, Chen J, Rondon G, MD, Popat U, MD, Parmar S, MBBS, Anderson B, Alousi AM, MD, Ahmed S, Bashir Q, MD, MBBS, Alatrash G, DO, PhD, Hosing C, Olson AL, MD, Mehta RS, MD, MPH, MS, Rezvani K, MD, PhD, Shpall EJ, MD, Khouri IF, Kebriaei P, MD, Champlin RE, MD. Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival. ASH 2017, 2017. e-Pub 2017.
58. Oran B, MD, MS, Garcia-Manero G, MD, Saliba RM, PhD, Alatrash G, DO, PhD, Jabbour EJ, MD, Popat U, MD, Ravandi F, MBBS, Alousi AM, MD, Kadia T, MD, Konopleva M, MD, PhD, DiNardo CD, MD, MSc, Pierce S, BSN, BA, Rezvani K, MD, PhD, Shpall EJ, MD, Sharma P, MD, PhD, Champlin RE, MD, Kantarjian HM, MD, Daver N, MD. Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade. ASH 2017, 2017. e-Pub 2017.
59. Gowda L, MD, Saliba RM, PhD, Shah MV, MD, PhD, Rondon G, MD, Badar I, MBBS, Olson AL, MD, Ciurea SO, MD, Kebriaei P, MD, Srour SA, Parmar S, MBBS, Nieto Y, MD, PhD, Ahmed S, MD, Mehta RS, MD, MPH, MS, Alatrash G, DO, PhD, Marin DC, M, Andersson BS, MD, PhD, Oran B, MD, MS, Bashir Q, MD, MBBS, Qazilbash MH, MD, Hosing C, MD, Khouri IF, Alousi AM, MD, Anderlini P, MD, Shpall EJ, MD, Rezvani K, MD, PhD, Champlin RE, MD, Popat U, MD. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. ASH 2017, 2017. e-Pub 2017.
60. Oran B, MD, MS, Saliba RM, PhD, Jorgensen JL, MD, PhD, Shah MV, MD, PhD, Marin DC, MD, Wang SA, MD, Ahmed S, MD, Alousi AM, MD, Andersson BS, MD, PhD, Bashir Q, MD, MBBS, Ciurea SO, Rezvani K, MD, PhD, Popat U, MD, Rondon G, MD, Kebriaei P, MD, Shpall EJ, MD, Champlin RE, MD. The Prognostic Impact of Minimal Residual Disease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia. ASH 2017, 2017. e-Pub 2017.
61. Saliba RM, Song HW, Maher OM, Overman BJ, Hofferek CJ, Pham AV, Chen J, Shpall EJ, Khouri IF, Champlin RE, Oran B, Ahmed S, Alousi AM, Tran DQ. Higher frequency of switched memory b cells predicts the incidence of chronic graft-versus-host disease after allogeneic stem cell transplantation. EHA 2017, 2017. e-Pub 2017.
62. Cerrada L, Sara, Saliba, Rima, Srour, Samer, Ahmed, Sairah, Hosing, Chitra, Champlin, Richard, Nieto, Yago. The Cell of origin has no prognostic impact on high dose chemotherapy with r-beam and autologous stem cell transplant for diffuse large b cell lymphoma. EBMT 2017, 2017. e-Pub 2017.
63. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing CM, Kebriaei P, Oran B, Nieto Y, Olson A, Ciurea SO, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. ASBMT 2017, 2017. e-Pub 2017.
64. Shah MV, Saliba RM, Jorgensen JL, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients. ASBMT 2017, 2017. e-Pub 2017.
65. Lindsay R, Saliba R, Choi H, Ping Z, Ramlal R, Alousi AM, Jones RB, Champlin RE, R Popat AU. Transfusion History Is the Most Significant Predictor of Iron Overload after Allogeneic Stem Cell Transplantation. ASBMT 2016, 2016. e-Pub 2016.
66. Srour SA, Saliba RM, Delgado R, Qazilbash MH, Bashir Q, Shah N, Popat UR, Ahmed S, Patel K, Jones R, Rondon G, Champlin RE, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. ASH 2016, 2016. e-Pub 2016.
67. Maher OM, Saliba RM, Alousi AM, Champlin RE, Shpall EJ, Tewari P, Hymes SR, Neumann JL, Overman BJ, Chen J, Rondon G, Song HW, Hofferek CJ, Tran DQ. High TCR Vbeta Skewing in CD4+ and Low in CD8+ Is Associated with Development of Chronic Graft-Versus-Host Disease. ASH 2016, 2016. e-Pub 2016.
68. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing C, Kebriaei P, Nieto Y, Oran B, Olson A, Ciurea SO, Rezvani K, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. ASH 2016, 2016. e-Pub 2016.
69. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Khouri IF, Nieto Y, Popat UR, Marin D, Rezvani K, Kebriaei P, Shah N, Olson AL, Shpall EJ, Champlin RE, Oran B. Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. ASH 2016, 2016. e-Pub 2016.
70. Cornelison M, Saliba RM, Ahmed S, Nieto Y, Bashir Q, Shah N, Parmar S, Patel K, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. ASH 2016, 2016. e-Pub 2016.
71. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat UR, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes. ASH 2016, 2016. e-Pub 2016.
72. Oran B, MD, Saliba RM, PhD, Carmazzi Y, Shpall EJ, MD, Rezvani K, MD, PhD, Lima MD, MD, Fernández-Viña M, Champlin RE, MD, Cao K, MS, MD. Increased Disease Progression in HLA-a, -B, -C, -DRB1 and -DBP1 Matched Recipients of Unrelated Donor Transplants with Peripheral Blood Is Independent of Risk Groups By Disease Risk Index. ASH 2015, 2015. e-Pub 2015.
73. Ragon BK, MD, Gulbis AM, Saliba RM, PhD, Chen J, Rondon G, MD, Popat UR, MD, Nieto Y, MD, PhD, Oran B, MD, Olson AL, MD, Patel K, MD, Hosing CM, MD, Qazilbash MH, MD, Shah N, MD, Kebriaei P, MD, Shpall EJ, MD, Champlin RE, MD, Alousi AM, MD. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. ASH 2015, 2015. e-Pub 2015.
74. Brammer JE, MD, Saliba RM, PhD, Jorgensen JL, MD, PhD, Ledesma C, Rondon G, MD, Poon M, Koh LP, Dibb W, BA, Fan G, MD, PhD, Saliba CK, Trainee C, Wang S, MD, Popat UR, MD, Shpall EJ, MD, Ravandi F, MD, Kantarjian H, MD, Maziarz RT, MD, Champlin RE, MD, Hosing CM, MD, Kebriaei P, MD. Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL). ASH 2015, 2015. e-Pub 2015.
75. Khouri IF, Saliba RM, PhD, Ledesma C, Jabbour EJ, MD, Turturro F, MD, Alatrash G, DO, PhD, Ahmed S, MD, Oran B, MD, Patel KK, Olson A, Marin D, MD, Popat UR, MD, Suki TS, Jorgensen JL, MD, PhD, Medeiros L, MD, Gulbis AM. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). ASH 2015, 2015. e-Pub 2015.
76. Mehta RS, MD, MPH, MS, Saliba RM, PhD, Chen J, Rondon G, MD, Hammerstrom AE, PharmD, BCOP, Alousi AM, MD, Qazilbash MH, MD, Bashir Q, MD, Ahmed S, MD, Popat UR, MD, Hosing CM, MD, Khouri IF, Shpall EJ, MD, Champlin RE, MD, Ciurea SO, MD. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. ASH 2015, 2015. e-Pub 2015.
77. Pingali SR, MD, Saliba R, Anderlini P, MD, Hosing CM, MD, Khouri IF, MD, Alousi AM, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Qazilbash MH, MD, Fanale MA, Shpall EJ, MD, Champlin RE, MD, Popat UR, MD. Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients. ASH 2015, 2015. e-Pub 2015.
78. Rondon G, MD, Saliba RM, PhD, Chen J, Ledesma C, Alousi AM, MD, Oran B, MD, Hosing CM, MD, Kebriaei P, MD, Khouri IF, Shpall EJ, MD, Popat UR, MD, Champlin RE, MD, Ciurea SO, MD. Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. ASH 2015, 2015. e-Pub 2015.
79. Khouri IF, Jabbour E, Saliba RM, PhD, Ledesma C, Burger JA, MD, PhD, O'Brien S, MD, Gulbis AM. Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT). ASH 2015, 2015. e-Pub 2015.
80. Im JS, MD, PhD, Saliba RM, PhD, Abraham SC, MD, Ross W, MD, Rondon G, MD, Rashid A, MD, Shpall EJ, MD, Popat UR, MD, Qazilbash M, MD, Hosing CM, MD, Oran B, MD, Shah N, MD, Champlin RE, MD, Alousi AM, MD. Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?. ASH 2015, 2015. e-Pub 2015.
81. Im JS, MD, PhD, Saliba RM, PhD, Abraham SC, MD, Rashid A, MD, Ross W, MD, Nieto Y, MD, PhD, Shpall EJ, MD, Oran B, MD, Olson A, Ahmed S, MD, Popat UR, MD, Rondon G, MD, Qazilbash MH, MD, Shah N, MD, Champlin RE, MD, Alousi AM, MD. Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease. ASH 2015, 2015. e-Pub 2015.
82. Mehta RS, MD, MPH, MS, Saliba RM, PhD, Cao K, MS, MD, Kaur I, PhD, Rezvani K, MD, PhD, Chen J, Olson A, Parmar S, MD, Shah N, MD, Marin D, MD, DM, MSc, Alousi AM, MD, Hosing C, MD, Popat UR, MD, Kebriaei P, MD, Champlin RE, MD, McNiece IK, PhD, Lima MD, MD, Skerrett D, Burke E, Shpall EJ, MD, Oran B, MD. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens. ASH 2015, 2015. e-Pub 2015.
83. Brammer JE, Saliba R, Kantarjian H, Thomas D, Jorgensen JL, Gaballa S, Ledesma C, Popat UR, Shpall EJ, Champlin RE, Hosing C, Kebriaei P. Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease and Prognostic Factors at the MD Anderson Cancer Center (MDACC). ASBMT 2015, 2015. e-Pub 2015.
84. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Atrash GA, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. ASBMT 2015, 2015. e-Pub 2015.
85. Sasaki K, MD, Saliba R, PhD, Lu G, MD, Shah N, MD, Bashir Q, MD, Patel K, MD, Bock F, MD, Parmar S, MD, Hosing C, MD, Popat UR, MD, Delgado R, Rondon G, MD, Champlin RE, MD, Qazilbash MH, MD. Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation. ASBMT 2015, 2015. e-Pub 2015.
86. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Champlin RE, Ciurea SO. Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation. ASBMT 2015, 2015. e-Pub 2015.
87. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. ASBMT 2015, 2015. e-Pub 2015.
88. Cornelison A, Saliba R, Ahmed S, Nieto YL, Bashir Q, Shah N, Parmar S, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Hematopoietic Stem Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) in the Inpatient (Inpt) Vs. Outpatient (Outpt) Settings: Impact of Hematopoietic Stem Cell Comorbidity Index (HCT-CI). ASBMT 2015, 2015. e-Pub 2015.
89. Afrough A, Saliba RM, Hamdi A, Fakih RE, Varma A, Dinh YT, Rondon G, Cornelison A, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. ASBMT 2015, 2015. e-Pub 2015.
90. Beitinjaneh A, Saliba RM, Medeiros L, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. ASBMT 2015, 2015. e-Pub 2015.
91. Gaballa S, Saliba R, Brammer JE, Lu G, Shah N, Bashir Q, Parmar S, Bock F, Hosing C, Popat UR, Delgado R, Rondon G, Shah J, Manasanch E, Orlowski RZ, Champlin RE, Qazilbash MH. Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience. ASBMT 2015, 2015. e-Pub 2015.
92. Popat UR, MD, Saliba R, PhD, Oran B, MD, Chen J, BS, Alousi AM, MD, Ahmed S, Bashir Q, MD, Ciurea SO, MD, Hosing C, MD, Jones RB, MD, PhD, Kebriaei P, MD, Khouri IF, MD, Nieto YL, MD, PhD, Olson A, MD, Parmar S, MD, Shah N, MD, Shpall EJ, MD, Qazilbash MH, MD, Andersson BS, MD, PhD, Champlin RE, MD. Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML. ASBMT 2015, 2015. e-Pub 2015.
93. Benjamin CL, Saliba R, Shpall EJ, de Lima MJ, John LS, Szabolcs P, Champlin RE, Komanduri KV. Baseline Thymopoietic Function and Post-Transplant Immune Recovery after Adult Cord Blood Transplantation. ASBMT 2014, 2014. e-Pub 2014.
94. Anderlini P, Saliba R, Ledesma C, Chancoco CM, Alexander TR, Alousi AM, Hosing C, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu SS, Younes A, Champlin RE. Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era. ASBMT 2014, 2014. e-Pub 2014.
95. Anderlini P, MD, Saliba R, PhD, Ledesma C, BS, Chancoco CM, Alexander TR, Alousi AM, MD, Hosing C, MD, Khouri IF, MD, Nieto Y, MD, PhD, Popat UR, MD, Shpall EJ, MD, Fanale MA, MD, Oki Y, MD, Romaguera JE, MD, Neelapu SS, MD, Younes A, MD, Champlin RE, MD. Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era. Blood 20(2):S72, 2014. e-Pub 2014.
96. Oran B, MD, Cao K, MD, Saliba RM, PhD, Chitra M Hosing MD, Uday R Popat MD, Lima MD, MD, Carmazzi Y, MS, Alousi A, MD, Partow Kebriaei MD, Yago Nieto MD, Gabriela Rondon MD, Willis D, Nina Shah MD, Simrit Parmar MD, Amanda Olson MD, Moore B, Richard E Champlin MD, Katayoun Rezvani MD, Shpall EJ, MD. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. BLOOD, 2014. e-Pub 2014.
97. Saliba RM, PhD, Kitko C, MD, Reddy P, MD, Magenau JM, MD, Pawarode A, Goldstein S, Couriel DR, MD. Prognostic Value of TGFβ at Diagnosis of Chronic GvHD. Blood(124):5875, 2014. e-Pub 2014.
98. Oran B, MD, Rima SM, MD, Andersson BS, MD, PhD, de Lima MJ, MD, Popat UR, MD, Khouri IF, MD, Kebriaei P, Bashir Q, Ahmed S, MD, Shpall EJ, MD, Champlin RE, Rondon G, MD. Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. BLOOD, 2014. e-Pub 2014.
99. Khouri IF, MD, Saliba RM, PhD, Xu-Monette ZY, PhD, Korbling M, MD, Rondon G, MD, Valverde R, Alousi AM, MD, Anderlini P, MD, Ahmed S, MD, Ciurea SO, MD, Fayad L, MD, Oran B, MD, Parmar S, Popat UR, MD, Westin JR, MD, Turturro F, MD, Medeiros L, MD, Gulbis AM, PharmD, BCOP, Young KH, MD, PhD. Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). BLOOD, 2014. e-Pub 2014.
100. Khouri IF, MD, Saliba RM, PhD, Challagundla P, Ledesma C, Korbling M, MD, Gulbis AM, PharmD, BCOP, Guillermo-Pacheco M, Ahmed S, MD, Anderlini P, MD, Bashir Q, MD, Betul Oran MD, Ciurea SO, MD, Hosing CM, MD, Kebriaei P, MD, Popat UR, MD, Jabbour E, MD, Champlin RE, MD, Jorgensen JL, MD, PhD. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. ASH 2013, 2013. e-Pub 2013.
101. Kitko CL, Saliba R, Paczesny S, Kennel M, Choi S, Reddy P, Levine J, Couriel DR. Non-Relapse Mortality in Chronic Graft Versus Host Disease: Risk Factors At Onset and Reponse to Treatment. Biology of Blood and Marrow Transplantation - ASBMT 2013 19(2), 2013. e-Pub 2013.
102. Kitko CL, Saliba R, Choi SW, Reddy P, Goldstein SC, Magenau J, Pawarode A, Kennel M, Levine JE, White E, Couriel DR. Biomarkers of Extracellular Matrix Remodeling in Chronic GVHD. Biology of Blood and Marrow Transplantation- ASBMT 2013 19(2), 2013. e-Pub 2013.
103. Anderlini P, MD, Saliba RM, PhD, Ledesma C, BS, Chancoco CM, Alexander T, PA, Alousi A, MD, Hosing CM, MD, Khouri I, MD, Nieto Y, MD, PhD, Popat UR, MD, Shpall EJ, MD, Fanale MA, MD, Oki Y, MD, Romaguera JE, MD, Neelapu S, MD, Younes A, MD, Champlin RE, MD. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). ASH 2013 Abstracts, 2013. e-Pub 2013.
104. Khouri IF, MD, Saliba RM, PhD, Xu-Monette ZY, MD, Rondon G, MD, Valverde R, MD, Korbling M, MD, Gulbis AM, PharmD, BCOP, Anderlini P, MD, Sairah A, MD, Hosing CM, MD, Popat UR, MD, Kebriaei P, MD, Fayad LE, Westin JR, MD, Turturro F, MD, Medeiros L, MD, Champlin RE, MD, Young KH, MD, PhD. Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). ASH 2013 Abstracts, 2013. e-Pub 2013.
105. Pingali SR, MD, Saliba RM, PhD, Smith VR, APN, Maadani F, Adekola KU, MBBS, Popat UR, MD, Qazilbash MH, MD, Bashir Q, MD, Khouri I, MD, Kebriaei P, MD, Ciurea SO, MD, Anderlini P, MD, Shah N, MD, Nieto Y, MD, PhD, Champlin RE, MD, Hosing CM, MD. Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia. ASH 2013 Abstracts, 2013. e-Pub 2013.
106. Jabbour EJ, MD, Kantarjian HM, MD, Oran B, MD, MS, Ravandi F, MD, Ghanem H, MD, Khouri I, MD, Garcia-Manero G, MD, Mathisen MS, PharmD, Bashir Q, MD, Saliba RM, PhD, Khouri M, Pierce SA, RN, BS, Brandt M, BS, Champlin RE, Lima MD, MD. Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
107. Ahmed S, MD, Saliba RM, PhD, Lima MD, MD, Fisher TD, MPAS, Rondon G, MD, Kebriaei P, MD, Alousi AM, MD, Hosing CM, MD, Bashir Q, MD, Andersson B, MD, PhD, Champlin RE. International Consensus Criteria for Tyrosine Kinase Inhibitor Response and Outcome of Allogeneic Stem Cell Transplantation for CML. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
108. Lima MD, MD, Parmar S, MD, Chen JJ, Giralt SA, MD, Rondon G, MD, Popat UR, MD, Alousi AM, MD, Lee HC, MD, Woodworth GG, RN, Hosing CM, MD, Shpall EJ, Kebriaei P, MD, Manero GG, MD, Champlin RE, Saliba RM, PhD. Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
109. Ahmed S, MD, Saliba RM, PhD, Lima MD, MD, Rondon G, MD, Kebriaei P, MD, Fisher TD, MPAS, Jabbour E, MD, Chen J, Kantarjian H, MD, Anderlini P, MD, Alousi AM, MD, Hosing CM, MD, Andersson B, MD, PhD, Jones RB, MD, PhD, Qazilbash MH, MD, Shpall EJ, MD, Giralt S, MD, Champlin RE, MD. Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
110. Alousi AM, MD, Saliba RM, PhD, Chen J, Andersson BS, MD, PhD, Khouri I, MD, Qazilbash MH, MD, Popat UR, MD, Hosing CM, MD, Ciurea SO, Shpall EJ, MD, Jones RB, MD, PhD, Kebriaei P, MD, Nieto Y, MD, PhD, Anderlini P, MD, DeLima M, MD, Rondon G, Champlin RE. A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
111. Lee HC, MD, Saliba RM, PhD, Rondon G, MD, Chen J, Charafeddine Y, Medeiros L, MD, Lima MD, MD, Andersson BS, MD, PhD, Kebriaei P, MD, Oran B, MD, MS, Champlin RE. Early Mixed T-Lymphocyte and Myeloid Chimerism Is Predictive of Disease Recurrence Following Allogeneic Stem Cell Transplantation for AML/MDS. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
112. Khouri IF, MD, Rima SM, MD, Turturro F, MD, Korbling M, MD, Ledesma C, Rondon G, MD, Alousi AM, MD, Anderlini P, MD, Bashir Q, MD, Ciurea SO, Hosing CM, MD, Popat UR, MD, Charafeddine Y, Oki Y, MD, Fayad LE, MD, Champlin RE. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
113. Kitko CL, Saliba RM, PhD, Paczesny S, MD, PhD, Kennel M, BS, MS, Choi SW, MD, Reddy P, MD, Levine JE, MD, MS, Couriel DR, MD. Risk Factors for Non-Relapse Mortality in Chronic Graft Versus Host Disease: Predicting Outcomes At Disease Onset. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
114. Hamdi A, MD, Poon LM, MD, Saliba RM, PhD, Rondon G, MD, Ledesma C, Qazilbash M, MD, Hosing CM, MD, Jones RB, MD, PhD, Popat UR, MD, Nieto Y, MD, PhD, Alousi AM, MD, Ciurea SO, Shpall EJ, MD, Champlin RE, Kebriaei P, MD. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
115. Bayraktar UD, MD, Saliba RM, PhD, Rondon G, MD, Stasi AD, MD, Kebriaei P, MD, Lima MD, MD, Champlin RE, Ciurea SO. Relevance and Factors Predicting for Early Lymphocyte Recovery After Allogeneic Bone Marrow Stem Cell Transplantation (BMT). ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
116. Benton CB, MD, Konopleva M, MD, PhD, Saliba RM, PhD, Shpall EJ, MD, Ciurea SO, Kebriaei P, MD, Alousi AM, MD, Popat UR, MD, Anderlini P, MD, Nieto Y, MD, PhD, Parmar S, MD, Zeng Z, MD, Chen JJ, Rondon G, MD, McMullin B, RN, Wang R, MD, PhD, Lu H, MMSC, Schober WD, MLT, Woodworth GG, RN, Gulbis A, PharmD, Cool R, Qiao W, Thall PF, PhD, Andreeff M, MD, PhD, Champlin RE. Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse. ASH Annual Meeting 2012 Abstract, 2012. e-Pub 2012.
117. Beitinjaneh A, Jakob J, Saliba R, Chen J, Rondon G, Giralt S, Cortes JE, Champlin R, Lima M. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Third Remission. ASBMT 2012 Meeting Abstract, 2012. e-Pub 2012.
118. Wilhelm K, Gulbis A, Maewal I, Cool R, Ferguson J, Westmoreland M, Martinez C, Saliba R, Rondon G, Chemaly R, Champlin R, Kebriaei P. The Impact of Pre-Transplant Valganciclovir on Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplant. ASBMT 2012 Meeting Abstract, 2012. e-Pub 2012.
119. Zhou Y, MD, PhD, Jorgensen JL, MD, PhD, Saliba RM, PhD, Wang SA, MD, Rondon G, MD, Ledesma C, BS, Andersson BS, MD, PhD, de Lima MJ, MD, Shpall EJ, MD, Popat U, MD, Ciurea SO, MD, Alousi AM, MD, Qazilbash M, MD, Hosing CM, MD, Medeiros L, MD, Champlin R, MD, Kebriaei P, MD. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
120. Kota V, MBBS, Saliba RM, PhD, Bayraktar UD, MD, Beitinjaneh A, MD, Chen JJ, Parmar S, MD, Giralt SA, MD, Rondon G, MD, , Ciurea SO, MD, Kebriaei P, MD, Qazilbash MH, MD, Andersson BS, MD, PhD, , Champlin R, MD, Lima MD, MD. Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
121. Chakhachiro ZI, MD, Saliba RM, PhD, Okoroji G, Korbling M, MD, Alousi AM, MD, Hosing CM, MD, Lima MD, MD, Anderlini P, MD, Popat U, MD, Samuels BI, MD, Medeiros L, MD, Bueso-Ramos CE, MD, PhD, Champlin R, MD, Khouri IF, MD. 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
122. Ciurea SO, MD, Saliba RM, PhD, Bayraktar UD, MD, Xie S, Rondon G, MD, Parmar S, MD, Kebriaei P, MD, Montes N, PA, Sharma M, MD, Konopleva M, MD, PhD, Nieto Y, MD, PhD, Qazilbash MH, MD, Alousi AM, MD, Andersson BS, MD, PhD, Hosing CM, MD, Shpall EJ, MD, Khouri IF, MD, Lima MD, MD, Champlin R, MD. Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT). ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
123. Andersson BS, MD, PhD, de Lima MJ, MD, Saliba RM, PhD, Shpall EJ, MD, Popat U, MD, Jones R, MD, PhD, Nieto Y, MD, PhD, Hosing CM, MD, Kebriaei P, MD, Alousi AM, MD, Worth LL, MD, PhD, Madden T, PharmD, Gulbis A, PharmD, Chen JJ, Rondon G, MD, McAdams P, RN, McMullin B, RN, Andreeff M, MD, PhD, Champlin R, MD. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS ; Results of a Randomized Phase III Study. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
124. Khouri IF, MD, Saliba RM, PhD, Korbling M, MD, Alousi AM, MD, Popat UR, MD, Anderlini P, MD, Ciurea SO, MD, Kebriaei P, MD, Qazilbash MH, MD, Champlin R, MD, Bassett Jr RL. Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. ASH Annual meeting 2011 Abstract, 2012. e-Pub 2012.
125. Hsu Y, Saliba RM, PhD, Okoroji G, o'Brien S, Ferrajoli A, MD, Abruzzo LV, MD, PhD, Champlin R, MD, Keating MJ, MD, Khouri IF, MD. Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
126. Beitinjaneh A, MD, MPH, Saliba RM, PhD, Okoroji G, Korbling M, MD, Alousi AM, MD, Popat U, MD, Anderlini P, MD, Bashir Q, MD, Andersson BS, MD, PhD, Kebriaei P, MD, Hosing CM, MD, Qazilbash M, MD, Fanale MA, MD, Pro B, MD, Champlin R, MD, Khouri I, MD. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
127. Bayraktar UD, MD, Lima MD, MD, Rima SM, MD, Maloy M, Castro-Malaspina H, MD, Chen JJ, Rondon G, MD, Chiattone A, MD, Jakubowski AA, MD, PhD, Boulad F, MD, Kernan NA, MD, O'Reilly RJ, MD, Champlin R, MD, Giralt SA, MD, Andersson BS, MD, PhD, Papadopoulos EB, MD. Ex-Vivo T Cell-Depleted Versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission: A Comparison of Outcomes in Two Institutions. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
128. Anguita T, MD, Chiattone A, MD, Hamerschlak N, MD, Saliba RM, PhD, Tang X, MD, Wu D, MD, Majilis A, MD, Sakashita AM, MD, Chiattone VC, RN, Barros JC, MD, Chiattone CS, MD, PhD, Kutner JM, MD, PhD, Rodrigues M, MD, Kondo AT, MD, Okoroji G, do Nascimento CMB, MD, Fernandes JF, MD, Popat U, MD, Champlin RE, MD, Anderlini P, MD, Lima MD, MD, Hosing CM, MD. Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
129. Kebriaei P, MD, Wilhelm K, Ravandi F, MD, Saliba RM, PhD, Lima MD, MD, Ciurea SO, MD, Worth LL, MD, PhD, O'Brien S, MD, Thomas DA, MD, Champlin R, MD, Kantarjian HM. Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
130. Zipp L, MS, Saliba RM, PhD, Valverde R, Okoroji G, Korbling M, MD, Samuels BI, MD, Abruzzo LV, MD, PhD, Alousi AM, MD, Andersson BS, MD, PhD, Hosing CM, MD, Erwin B, MS, Anderlini P, MD, Popat UR, MD, Kebriaei P, Macapinlac HA, MD, Champlin R, MD, Khouri IF, MD. Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
131. Khouri IF, MD, Saliba RM, PhD, Valverde R, Samuels BI, MD, Korbling M, MD, Alousi AM, MD, Anderlini P, MD, Bashir Q, MD, Lima MD, MD, Hosing C, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Popat UR, MD, Qazilbash M, MD, Neelapu S, MD, Fowler NH, MD, Samaniego F, MD, Wang L, MD, Champlin R, MD, Macapinlac HA, MD. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
132. Saliba RM, PhD, Chiattone A, MD, Majlis A, MD, Chiattone VC, RN, Rondon G, MD, Sakashita AM, MD, Hamerschlak N, MD, Kutner JM, MD, PhD, Shpall EJ, MD, Anderlini P, MD, Khouri I, MD, Qazilbash MH, MD, Popat U, MD, Champlin R, MD, Hosing CM, MD, Lima MD, MD. Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization. ASH Annual Meeting 2022 Abstract, 2012. e-Pub 2012.
133. Anderlini P, MD, Saliba RM, PhD, Ledesma C, BS, Chancoco CM, Acholonu S, Valverde R, Popat UR, MD, Hosing CM, MD, Alousi AM, MD, Shpall EJ, MD, Nieto Y, MD, PhD, Ciurea SO, MD, Khouri I, MD, Champlin R, MD. Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL). ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
134. Patel K, Saliba RM, Shah N, Bashir Q, Thomas SK, Dinh YT, Hosing CM, Popat UR, Parmar S, Giralt SA, Champlin RE, H Qazilbash AM. Autologous Stem Cell Transplantation in Waldenstrom's Macroglobulinemia. Blood ASH Annual Meeting 2012, 2012. e-Pub 2012.
135. Khouri IF, Saliba R, Korbling M, Alousi AM, Popat UR, Anderline P, Kebriaei P, Qazilbash M, Champlin RE, Bassett RL. Bendamustine in combination with fludarabine and rituximab: A novel nonmyeloablative conditioning for allogeneic stem cell transplantation (AST) in patients with lymphoid malignancies. ASCO Meeting Abstracts. 2011 29(15):(May Supplement 2011), 2011. e-Pub 2011.
136. Beitinjaneh A, Saliba R, Okoroji G, Alousi AM, Popat UR, Korbling M, Anderlini P, Qazilbash M, Kebriaei P, Hosing C, Champlin RE, Khouri IF. Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. ASCO Meeting Abstracts. 2011 29(15):(May Supplement 2011), 2011. e-Pub 2011.
137. Saliba RM, Lima M, McMannis J, Robinson S, Shpall E, Champlin RE, Bosque DM, Parmar S, Rondon G, Simmons P, Alousi A. Dynamics of Recovery in Double Umbilical Cord Blood Transplantation With an ex-vivo Mesenchymal Cell Expanded Unit: Faster Recovery With Engraftment of the Expanded Unit. Biology of Blood and Marrow Transplantation, 17(2):S318, 2011. e-Pub 2011.
138. Ciurea SO, Saliba RM, Rondon G, Sharma M, Montes N, Bosque D, McMannis J, Fernandez-Vina M, Xie S, Konopleva M, Parmar S, Nieto Y, Kebriaei P, Quazilbash M, Alousi A, Popat U, Hosing CM, Shpall EJ, Khouri IF, Lima M, et al. Haploidentical Stem Cell Transplantation for Minorities. Biology of Blood and Marrow Transplantation 17(2):S227, 2011. e-Pub 2011.
139. Leen AM, Saliba R, Maewal I, Ku S, Katari U, Tripic T, Lima M, Alousi A, Shpall EJ, Bollard CM. Immune Reconstitution and Infectious Complications in Cord Blood Transplant Patients. Biology of Blood and Marrow Transplantation 17(2):S232, 2011. e-Pub 2011.
140. Ciurea SO, Saliba RM, Rondon G, Patah PA, Rodrigues, Aung FM, Andersson BS, Parmar S, Champlin RE, de Lima M, Fernandez-Vina M. Outcomes of Patients Treated with Matched and Mismatched Unrelated Donors Using High Resolution HLA Typing at 12 Loci. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
141. Okoroji GJ, De Padua Silva L, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri IF. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
142. Chiattone A, Saliba RM, Andersson BS, Giralt S, Sharma MR, Rondon G, Kebriaei P, Hosing C, Popat U, Parmar S, Alatrash G, Bashir Q, Chen JJ, Yuen C, Chiattone VC, Champlin RE, de Lima M. Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA). Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
143. Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung FM, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M Champlin RE, de Lima M. Superior Outcomes with Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors In Allogenic Hematopoietic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
144. de Lima M, Robinson S, McMannis J, Alousi AM, Saliba RM, Munsell M, Kebriaei P, Hosing C, Parmar S, Cooper L, Shah N, Staba Kelly S, Rondon G, Fernandez-Vina M, Maewall I, Bosque D, Bollard CM, Chen JJ, McNiece IK, Komanduri KV, Nieto Y, Jones R, Andersson BS, Popat U, Champlin RE, Simmons PJ, Shpall EJ. Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (EXP) Leads to Rapid Engraftment of Platelets and Neutrophils. Blood (ASH Annual Meeting Abstracts 116, 2010. e-Pub 2010.
145. Sharma M, Saliba RM, Qazilbash MH, Okoroji GJ, Popat U, de Lima M, Champlin R, Hosing C. Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
146. Alousi AM, Andersson BS, Saliba RM, Botnick W, Rondon G, Shpall EJ, de Lima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash MH, Anderlini P, Nieto Y, Ciurea S, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced hematological Malignancies. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
147. Kebriaei P, Chiattone A, Saliba R, Jones D, Anderlini P, Andersson B, Khouri I, Worth L, Ravandi F, Thomas D, Kantarjian H, Hamerschlak N, Rodrigues M, de Lima M, Giralt S, Champlin R. Imatinib Maintenance Following Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Philadelphia Chromosome Positive (PH+) Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation 16(2):Sup. S230, 2010. e-Pub 2010.
148. Ciurea SO, de Lima M, Kebriaei P, Rondon G, Saliba R, McMannis J, Andersson BS, Khouri IF, Giralt S, Champlin RE. Safety Of T-Cell Replete Haploidentical Stem Cell Transplantation Using Fludarabine, Melpahalan And Thiotepa Conditioning And High-Dose Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation 16(2):Supp. S218, 2010. e-Pub 2010.
149. Yuen CH, Rm S, Anderssson BS, Shpall E, Popat UR, Qazilbash MH, Hosing C, de lima M, Giralt SA, Champlin RE, Kebriaei P. Faster Lymphocyte Recovery After Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts For Decreased Non-Relapse Mortality (NRM) In Adults With Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation 16(2):Supp. S283, 2010. e-Pub 2010.
150. Alousi AM, Rondon G, Okorji GJ, Popat U, De Padua Silva L, Hymes S, Neumann J, Brunell NM, Kebriaei P, Hosing C, Khouri IF, Shapll EJ, Qazilbash MH, Giralt S, Champlin R, Saliba RM. Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). Blood (ASH Annual Abstracts) 114(22):884, 2009. e-Pub 2009.
151. De Padua Silva L, Saliba R, McCormick D, Okoroji GJ, Alousi A, Anderlini P, Ciurea S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, McMannis J, Champlin R, Pro B, Khouri IF. Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). Blood (ASH Annual Abstracts) 114(22):1245, 2009. e-Pub 2009.
152. Kebriaei P, Saliba R, Rondon G, Worth L, Cooper LJN, Thomas DA, Kantarjian H, de Lima M, Champlin RE, Giralt S. Second Allogeneic Transplants for Relapsed Acute Lymphoblastic Leukemia Result in High Response Rates of Short Duration: Further Intervention Is Required to Maintain Response. Blood (ASH Annual Abstracts) 114(22), 2009. e-Pub 2009.
153. Alatrash G, Andersson B, Pelosini M, Rondo G, Qazilbash M, Giralt S, de Padua S, Hosing C, Kebriaei, P, Zhang W, Saliba R, Champlin R, de Lima M. Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Patients In the 6th and 7th Decades Of Life With AML OR MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BUFLU) Conditioning Regimen. ASBMT (Annual Meeting Abstracts) 2009 15(2(2)):106, 2009. e-Pub 2009.
154. Saliba RM, Komanduri KV, Koca E, Alousi A, Giralt S, Andersson BS, Zhang W, Rondon G, Neumann J, Popat UR, Kebriaei P, de Lima M, Champlin RE. High Rate OF DE NOVO Chronic Graft-Versus-Host (CGVHD) Following Busulfan-Fludarabine Conditioning And Allogeneic Stem Cell Transplantation From A Matched-Sibling Donor (MSD) For AML/MDS. ASBMT (Annual Meeting Abstracts) 2009 15(2(2)):122, 2009. e-Pub 2009.
155. Efebera Y, Saliba RM, Thandi RS, Popat U, de Lima M, Alousi A, Hosing C, Ledford M, Champlin R, Giralt S. Impact Of Pre-Stem Cell Transplant Ferrintin Levels On Late Transplant Complications. A Landmark Analysis to Determine Potential Role Of Iron Chelation In Improving Transplant Outcomes. ASBMT (Annual Meeting Abstracts) 2009 15(2(2)):92, 2009. e-Pub 2009.
156. Alatrash G, Pelosini M, Saliba R, Rondon G, Zhang W, Giralt S, Kebriaei P, Alousi A, Khouri I, Champlin R, de Lima M. Post-Hematopoietic Stem Cell Tranplantation (HSCT) Outcomes in Patients with AML Transplanted Prior To Achieving Platelet Recovery. ASBMT (Annual Meeting Abstracts) 2009 15(2):28, 2009. e-Pub 2009.
157. Koca E, Saliba RM, de Lima M, Popat U, Kebriaei P, Rondon G, Zhang W, Giralt S, Andersson BA, Champlin R. Impact Of Cytogenetics And Marrow Remission Status On Disease Progression In Patients With Acute Myeloid Leukemia (AML) OR Myelodysplastic Syndrome (MDS) Undergoing Allogeneic Stem Cell Transplantation. ASBMT (Annual Meeting Abstracts) 2009 15(2(2)):99, 2009. e-Pub 2009.
158. Khan ZU, Saliba RM, Qureshi S, Hosing C, Giralt SA, delima MJ, Yusuf SW, Popat UR, Champlin RE, Qazilbash MH. Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1135, 2008. e-Pub 2008.
159. de Lima M, McMannis JD, Saliba R, Worth L, Kebriaei P, Popat U, Qazilbash M, Jones R, Giralt S, de Padua Silva L, Cooper L, Petropoulos D, Lee D, Kelly S, Thall P, Robinson S, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson BS, Nieto Y, Ciurea S, Komanduri K, Champlin RE, Shpall E. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood (ASH Annual Meeting Abstracts) 2008 112(11):63, 2008. e-Pub 2008.
160. Giralt S, Saliba RM, Rondon G, de Padua Silva L, Alousi A, Popat U, De Lima M, Andersson B, Kebriaei P, Anderlini P, Hosing C, Jones R, Shpall EJ, Champlin RE, Khouri IF. Outcomes of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive Therapy with Curative Intent. Blood (ASH Annual Meeting Abstracts) 2008 112(11):750, 2008. e-Pub 2008.
161. Alatrash G, Pelosini M, Saliba RM, Rondon G, Zhang W, Giralt S, Kebriaei P, Alousi A, Khouri IF, Champlin RE, de Lima M. Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1031, 2008. e-Pub 2008.
162. de Padua Silva L, Patah P, Saliba RM, Szewczyk NA, Gilman L, Gulbis A, Neumann J, Walker J, Petropoulos D, LaSala R, Shaz Mir KA, Nieto Y, Khouri I, Giralt S, Champlin RE, de Lima M. Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic Cystitis (HC) Incidence. Blood (ASH Annual Meeting Abstracts) 2008 112(11):25, 2008. e-Pub 2008.
163. Joseph Jr RW, Komanduri KV, Saliba RM, Alousi A, Giralt S, Rondon G, Neumann J, Trevino C, Couriel DR, Champlin R, Popat U. High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients. Blood (ASH Annual Meeting Abstracts) 2008 112(11):745, 2008. e-Pub 2008.
164. Khalili JS, Saliba RM, St John L, Alousi A, Wieder ED, de Lima M, Champlin R, Molldrem JJ, Sphall EJ, McMannis J, Komanduri KV. Regulatory and Naïve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML. Blood (ASH Annual Meeting Abstracts) 2008 112(11):267, 2008. e-Pub 2008.
165. Silva DP, Saliba RM, Giralt S, de Lima M, Hosing C, Khouri IF, Popat U, Qazilbash M, Shpall E, Thomas DA, Kantarjian H, Champlin R, Kebriaei P. Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2008 112(11), 2008. e-Pub 2008.
166. Alatrash G, Andersson BS, Pelosini M, Rondon G, Qazilbash MH, Giralt S, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin RE, de Lima M. Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1031, 2008. e-Pub 2008.
167. Qazilbash MH, Saliba RM, Pelosini M, Hosing CM, Mendoza FL, Han E, Wang M, Weber DM, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, de Lima M, Orlowski RZ, Champlin RE, Giralt SA. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1140, 2008. e-Pub 2008.
168. Cole SM, Saliba R, Pelosini M, Mendoza FL, Weber D, Wang M, Thomas S, Orlowski RZ, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1132, 2008. e-Pub 2008.
169. Koca E, Saliba RM, de Lima M, Popat U, Kebriaei P, Rondon G, Giralt S, Andersson BS, Champlin RE. Impact of Pretransplant Cytogenetics and Marrow Remission Status on Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation Conditioned with Busulfan and Fludarabine. Blood (ASH Annual Meeting Abstracts) 2008 112(11):133, 2008. e-Pub 2008.
170. Popat U, Saliba R, de Padua S L, Andersson BS, Alousi AM, Anderlini P, de Lima M, Okoroji GJ, Hosing CM, Jones RB, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Champlin R, Giralt SA. Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood (ASH Annual Meeting Abstracts) 2008 112(11):297, 2008. e-Pub 2008.
171. Saliba RM, Komanduri KV, Koca E, Alousi AM, Giralt S, Andersson BS, Zhang W, Rondon G, Popat UR, Kebriaei P, de Lima M, Champlin RE. Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS. Blood (ASH Annual Meeting Abstracts) 2008 112(11):776, 2008. e-Pub 2008.
172. Silva L, Patah P, Szewczyk N, Saliba RM, Gilman L, Gulbis A, Neumann J, Walker JA, Petropolulos D, El-Zimaity M, Anderlini P, Tarrand J, Ciurea SO, Shpall EJ, Popat UR, Jones RB, Giralt SA, Champlin RE, de Lima M. A Prospective Evaluation of The Effect of Polyoma (BK) Virus Infection On the Incidence of Hemorrhagic Cystitis (HC) After Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT). Biology of Blood and Marrow Transplantation 14(2):102, 2008. e-Pub 2008.
173. Ramos CA, Saliba RM, Khorshid O, de Padua L, Giralt SA, Andersson BS, Ueno NT, Shpall EJ, Hosing C, Qureshi SR, Champlin RE, de Lima M. Serological Evidence of Hepatitis Is Associated With Worse Non-Relapse Mortality And Overall Survival After Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 14(2):103, 2008. e-Pub 2008.
174. Saliba RM, Couriel D, Komanduri K, Patah P, Westin J, Giralt SA, Cooper L, Petroplulos D, Worth L, Safdar A, Champlin RE, Shpall EJ, de Lima M. Incidence and Risk Factors For Chronic Graft-Versus-Host Disease (cGVHD) After Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 14(2):132, 2008. e-Pub 2008.
175. Ramos CA, Saliba RM, Giralt SA, Khorshid O, De Padua L, Andersson BS, Nieto YL, Popat UR, Qazilbash MH, Qureshi S, Zhang W, Champlin RE, de Lima M. The Impact of Resolved Hepatitis B Infection on Allogeneic Hematopoietic Stem Cell Transplantation For Hematological Malignancies. Biology of Blood and Marrow Transplantation 14(2):8, 2008. e-Pub 2008.
176. Williams LA, Giralt SA, Mendoza TR, Andersson KO, Mobley GM, Saliba RM, Qazilbash MH, Campagnaro EL, Cleeland CS. Larger Stem Cell Dose Is Associated With Decreased Symptom Severity After Autologous Stem Cell Transplantation For Multiple Myeloma. Biology of Blood and Marrow Transplantation 14(2):98, 2008. e-Pub 2008.
177. Popat UR, Saliba RM, Ablawat S, Okoroji GJ, Alousi A, Anderlini P, Andersson B, de Lima M, Jones RB, Kebriaei P, Korbling M, Nieto Y, Qazilbash MH, Shpall EJ, Khouri I, Giralt SA, Champlin RE, Hosing CM. Incidence and Factors Influencing Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). Biology of Blood and Marrow Tranplantation 14(2):37, 2008. e-Pub 2008.
178. Ramos CA, Saliba RM, Khorshid O, de Padua L, Giralt S, Andersson BS, Ueno NT, Shpall EJ, Khouri IF, Hosing C, Alousi A, Nieto Y, Qureshi SR, Champlin RE, de Lima M. Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies. Blood 110(11), 2007. e-Pub 2007.
179. Alousi A, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin PW, Pro B, Wang M, Rodriguez A, Hagemeister FB, Macapinlac HA, Podoloff DA, Champlin RE, Khouri IF. Zevalin®/BEAM/Rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL): impact of the IPI and PET status. Blood 110(11), 2007. e-Pub 2007.
180. Parikh GC, Saliba RM, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi A, Champlin RE, Giralt SA, Qazilbash MH. Autotransplantation in patients with multiple myeloma and concurrent renal failure is safe and feasible and associated with recovery of renal function in >30% of patients. Blood 110(11), 2007. e-Pub 2007.
181. Westin JR, Saliba RM, de Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Champlin R, Couriel DR. Risk factors for response after initial therapy for acute-graft-versus host disease (aGVHD). Blood 110(11), 2007. e-Pub 2007.
182. Couriel D, Patah P, Saliba R, Cooper L, Worth L, Petropoulos D, Depadua L, Zhang W, Giralt S, Champlin RE, Shpall EJ, de Lima M. Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes. Blood 110(11), 2007. e-Pub 2007.
183. Khouri IF, Saliba RM, Korbling M, Hosing C, Fayad L, Lee MS, Samaniego F, Samuels BI, Couriel D, Hagemeister F, McLaughlin P, Champlin RE. Nonmyeloablative allogeneic transplantation (NMT) for relapsed follicular lymphoma (FL): continuous complete remission with longer follow-up. Blood 110(11), 2007. e-Pub 2007.
184. Patah P, Saliba R, Fernandez-Vina M, Cano P, Pesoa S, Rondon G, Andersson BJ, Giralt SA, Kebriaei P, Hosing C, Anderlini P, Couriel D, Alousi A, Padua L, Ramos C, Champlin RE, de Lima M A. A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants. Blood 110(11), 2007. e-Pub 2007.
185. De Padua Silva L, Saliba RM, de Lima M, Okoroji GJ, Alousi A, Andersson B, Hosing CM, Sphall EJ, Khouri I, Qazilbash MH, Anderlini P, Kebriaei P, Champlin RE, Jones RB, Giralt S, Popat UR. Obesity Does Not Impact Outcome in Patients with AML/MDS Undergoing Allogeneic Transplantation. Blood - ASH Annual Meeting Abstracts 110(11):592A, 2007. e-Pub 2007.
186. Giralt S, Saliba R, Mendoza F, Parikh G, Qureshi S, Zhang W, Popat UR, Qazilbash MH, Khouri I, Hosing CM, Alousi A, Anderlini P, Andersson B, PhD, Jones RB, Shpall EJ, Kebriaei P, Nieto Y, Ueno N, Champlin RE, de Lima M. Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT). Blood - ASH Annual Meeting Abstracts 110(11):590A, 2007. e-Pub 2007.
187. Chu DT, Saliba RM, Qureshi S, Alousi A, Anderlini P, Bukhari F, Delima M, Giralt SA, Kebriaei P, MD, Khouri I, Parik G, Popat UR, Shpall EJ, Yusuf WS, Champlin RE, Qazilbash MH, Hosing CM. Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation. Blood - ASH Annual Meeting Abstracts 110(11):881A, 2007. e-Pub 2007.
188. Qazilbash MH, Saliba RM, Parikh G, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DR, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 110(11), 2007. e-Pub 2007.
189. Qazilbash MH, Saliba RM, Parikh G, Hosing CM, Mendoza F, Weber D, Wang M, Thomas SK, Flosser TS, Kebriaei P, Popat UR, Alousi AM, de Lima M, Champlin RE, Giralt SA. A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma. Blood - ASH Annual Meeting Abstracts 110(11):890A, 2007. e-Pub 2007.
190. Qureshi S, Bukhari F, Saliba RM, Hosing C, Champlin RE, Giralt SA, De Lima MJ, Yusuf SW, Qazilbash MH. Outcome of allogenic SCT in patients with low left ventricular ejection fraction. 2007 ASCO Annual Meeting Part I. Vol 25(No. 18S (June 20 Supplement)), 2007. e-Pub 2007.
191. Anderlini P, Saliba R, Acholonu S Giralt SA, Khouri IF, Andersson B, de Lima M, Hosing C, Champlin RE. Two-Year Follow-up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin's Lymphoma. BBMT 13(2), 2007. e-Pub 2007.
192. Qazilbash MH, Gul Z, Jindani S, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, t F, Couriel DR, de Lima M, kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma. BBMT 13(2), 2007. e-Pub 2007.
193. Qazilbash MH, Jindani S, Gul Z, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DR, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, Giralt SA. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. BBMT 13(2), 2007. e-Pub 2007.
194. Saliba RM, Komanduri K, Grialt S, de Souza J, Patah PA, Oran B, Rondon G, Couriel DR, Champlin R, de Lima M. Correlates and Outcome of Absolute Lymphocyte Count (ALC) on Day 30 Post Allogeneic Stem Cell Transplantation (SCT) for Treatment of AML. BBMT 13(2), 2007. e-Pub 2007.
195. Qazilbash MH, Saliba R, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, de Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma. Blood 108(11), 2006. e-Pub 2006.
196. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Kebriaei P, Ali T, de Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin s Lymphoma (NHL) in Patients over 65 Years of Age. Blood 108(11), 2006. e-Pub 2006.
197. Khouri IF, Saliba RM, Admirad J, O'Brien S, Lee MS, Samuels BI, Giralt S, de Lima M, Keating M, Champlin RE, Bueso-Ramos C. ZAP-70 Status Does Not Predict Outcome after Nonmyeloablative Allogeneic Stem-Cell Transplantation (NST) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) That Fails To Respond to Conventional Chemo immunotherapy. Blood 108(11), 2006. e-Pub 2006.
198. Patah PA, Gurkan E, Saliba R, de Lima M, Rondon G, Ramos CA, Couriel D, deSouza JA, Champlin R, Lichtiger B. Prophylactic Platelet (PLT) Transfusions in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): Similar Clinical Efficacy of Single Donor (SDP) and Random Donor Pooled (RDP) Platelet Products. Blood 108(11), 2006. e-Pub 2006.
199. Qazilbash MH, Saliba RM, Davis MS, Mendoza FL, Hosing C, Couriel DR, de Lima M, Kebriaei P, Weber DM, Wang M, Alousi AM, Mathes SG, Jones RB, Re C, Giralt SA. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood 108(11), 2006. e-Pub 2006.
200. Saliba RM, Khouri IF, de Lima M, Hosing C, Okoroji G, Acholonou S, Maadani F, DeJesus J, Hsu Y, Champlin RE, Couriel DR. Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin s Lymphoma. Blood 108(11), 2006. e-Pub 2006.
201. de Lima M, Patah PA, Saliba R, Couriel D, Chan K, Worth L, Giralt S, Kebriaei P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulous D, Jd M, Hosing C, Rondon G, Komanduri KV, Champlin RE, Shpall EJ. Donor-Recipient Host-Versus-Graft (HVG) HLA Mismatches and Outcome of Cord Blood Transplants (CBT). Blood 106(11), 2006. e-Pub 2006.
202. Shpall EJ, Karandish S, Sadeghi T, Hosing C, Gracia CJ, Cherry MT, Walker JA, Denman CR, Saliba RM, Champlin RE, Fernandez Vina M, Cano P, McMannis JD. In Utero Is Superior to Ex Utero Cord Blood Collection. Blood 108(11), 2006. e-Pub 2006.
203. Ahmed B, Saliba RM, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber T, Want M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Blood 108(11), 2006. e-Pub 2006.
204. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Farzaneh M, Korbling M, Okoroji GJ, Stachowiak AM, Samuels BI, Anderlini P, Kebriaei P, Ueno NT, Qazilbash MH, McLaughlin PW, Hagemeister FB, Younes A, Podoloff DA, Champlin RE. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin s Lymphoma (NHL). Blood 108(11), 2006. e-Pub 2006.
205. Anderlini P, Saliba RM, Acholonu S, Giralt SA, Khouri IF, Andersson B, de Lima MJ, Hosing C, Couriel D, Champlin RE. Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin s Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors. Blood 108(11), 2006. e-Pub 2006.
206. de Souza JA, Saliba R, Patah PA, Rondon G, Qazilbash M, Hosing C, Popat U, Champlin RE, de Lima M. Renal Function Impairment and Outcomes of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Blood 108(11), 2006. e-Pub 2006.
207. Alousi AM, Saliba RM, Okoroji G, Hosing C, Samuels BI, Champlin RE, Khouri IF. The influence of PET/Gallium (P/G) status and high-dose rituximab (HDR) in patients (pts) with aggressive, large, B-cell lymphoma (LBCL) receiving autologous stem cell transplants (ASCT). 2006 ASCO Annual Meeting 24(No. 18S (June 20 Supplement), 2006. e-Pub 2006.
208. Qazilbash MH, Saliba R, Mendoza F, Roden L, Hosing C, Couriel D, Kebriaei P, Popat U, de Lima M, Champlin RE, Giralt S. Salvage autologous transplantation in multiple myeloma. BBMT 12(2), 2006. e-Pub 2006.
209. Qazilbash MH, Saliba R, Mendoza F, Roden L, Hosing C, Couriel DR, Kebriaei P, Popat U, de Lima M, Champlin RE, Giralt S. Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma. BBMT 12(2), 2006. e-Pub 2006.
210. Mickler KL, Saliba R, Ghosh S, de Lima M, Giralt S, Kim S, Andersson B, Khouri I, Champlin RE, Couriel D. The risk of graft-versus-host disease (GVHD) varies with different myeloablative regimens: IV Busulfan/Fludarabine (IV BuFlu) versus IV Busulfan/Cyclophosphamide (IV BuCy) versus Fludarabine/Melphalan (FM). BBMT 12(2):Suppl 1, 2006. e-Pub 2006.
211. Couriel DR, Saliba RM, Ghosh S, de Lima M, Giralt S, Khouri I, Andersson B, Mickler K, Caldera Z, Hsu Y, Neumann J, Hymes S, Kim S, Champlin R. Chronic or acute? GVHD beyond day 100. BBMT 12(2):Suppl. 1, 2006. e-Pub 2006.
212. Blackburn RK, Giralt SA, Saliba RM, Rondon G, Fenwick JN. Acute hypertensive crisis during infusion of hematopoietic progenitor cell from matched unrelated donors: identification of predictive factors and optimal treatment. BBMT 12(2):Suppl 1, 2006. e-Pub 2006.
213. Saliba RM, Oran B, Giralt S, Komanduri K, Carrasco-Yalan A, Ghosh S, Champlin R, de Lima M. Disease status at transplant impacts lymphocyte and platelet recovery after allogeneic peripheral blood stem cell transplant (PBSCT) for patients with AML/MDS. BBMT 12(2):Suppl. 1, 2006. e-Pub 2006.
214. Ativitavas T, Saliba R, Giralt S, Ghosh S, Champlin R, de Lima M. Treatment of myelodysplastic syndromes with allogeneic hematopoietic stem cell transplantation(HSCT)-Impact of non-relapse mortality on outcomes. BBMT 12(2):Suppl 1, 2006. e-Pub 2006.
215. Campagnaro E, Saliba R, Anderson K, Roden L, Mendoza F, Aleman A, Cleeland C, Weber D, Brown J, Giralt S. Risk factors for development of symptoms after autologous transplantation for multiple myeloma. BBMT 12(2):Suppl 1, 2006. e-Pub 2006.
216. Saliba R, de Lima M, Hosing C, Khouri IF, Giralt S, Anderlini P, Ghosh S, Mickler K, Ippoliti C, Caldera Z, Hsu Y, Neumann J, Champlin R, Couriel DR. Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease. Blood 106(11), 2005. e-Pub 2005.
217. Kebriaei P, Saliba R, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL). Blood 106(11), 2005. e-Pub 2005.
218. Kebriaei P, Saliba R, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL). Blood 106(11), 2005. e-Pub 2005.
219. Oran B, Lee H, de Lima M, Couriel D, Giralt S, Saliba R. Steroid Complications in Patients with Acute Graft Versus Host Disease. Blood 106(11), 2005. e-Pub 2005.
220. Khouri IF, Saliba RM, Hosing C, Acholonu S, Fayad LE, Korbling M, Saenz C, Pro B, Samuels B, de Lima M, Giralt S, Younes A, McLaughlin P, Champlin RE. Autologous Stem Cell (AUTO) vs. Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL). Blood 106(11), 2005. e-Pub 2005.
221. Hosing C, Saliba RM, De Lima M, Giralt S, Ghosh S, Hsu Y, Anderlini P, Hymes SR, Andersson B, Khouri IF, Champlin RE, Couriel D. Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors. Blood 106(11), 2005. e-Pub 2005.
222. Oran B, Saliba R, Giralt S, Couriel D, Carrasco-Yalan A, Hosing C, Shahjahan M, de Meis E, Anagnostopoulos A, Anderlini P, Ghosh S, Khouri I, Champlin R, LimaM D. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS. Blood 106(11), 2005. e-Pub 2005.
223. Couriel DR, Saliba R, Gosh S, de Lima M, Giralt S, Khouri I, Andersson B, Mickler K, Caldera Z, Hsu Y, Neumann J, Hymes S, Kim S, Champlin RE. The Clinical Spectrum of Acute GVHD: Beyond Day 100. Blood 106(11), 2005. e-Pub 2005.
224. Korbling M, Reuben J, Gao H, Lee BN, Giralt S, Khouri IF, Saliba R, Champlin RE, Estrov Z. RhG-CSF Mobilized and Apheresis-Collected Endothelial Progenitor Cells for Therapeutic Vasculogenesis. Blood 106(11), 2005. e-Pub 2005.
225. Khouri IF, Saliba R, Lee MS, Okoroji GJ, Fayad L, Maadani F, HosingC, Samuels B, Giralt S, de Lima M, Pro B, Younes A, McLaughlin P, Kwak L, Champlin RE. Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin's Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease. Blood 106(11), 2005. e-Pub 2005.
226. Khouri IF, Lee MS, Saliba R, Acholonu SA, Valverde R, Korbling M, Champlin RE. Non-Myeloablative Allogeneic Transplantation (NMT) with T-Cell Replete Graft for Relapsed Chemosensitive Follicular Lymphoma (FL): Donor Lymphocyte Infusion (DLI) To Convert Stable Mixed Chimerism to Full Donor Chimerism Is Not Necessary in the Absence of Disease Progression. Blood 106(11), 2005. e-Pub 2005.
227. Khouri IF, Tarrand JJ, Okoroji GJ, Saliba R, Hosing C, Couriel D, Kebriaei P, Griffith D, Rondon G, Ippoliti C, Champlin RE. Campath-IH Combined with Fludarabine/Cyclophophamide/ Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin's Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation. Blood 106(11), 2005. e-Pub 2005.
228. Campagnaro E, Saliba R, Anderson K, Roden L, Mendoza F, Aleman A, Cleeland D, Weber D, Brown J, Giralt S. Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myelom. Blood 106(11), 2005. e-Pub 2005.
229. Couriel DR, Thall P, Mickler K, De Lima M, Giralt S, Qazilbash MH, Hosing C, Khouri I, Kebriaei P, Hsu Y, Saliba R, Ippoliti C, Champlin RE. Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD). Blood 106(11), 2005. e-Pub 2005.
230. Khouri IF, Keating MJ, Saliba RM, O’brien S, Champlin RE, Bueso-Ramos, C. The Efficacy of Non-Myeloablative Allogeneic Stem Cell Transplantation in ZAP-70 Positive/Chemo-Antibody Refractory Patients with Chronic Lymphocytic Leukemia (CLL). 2005 ASCO Annual Meeting Proceedings 23(No. 16S, Part I of II (June 1 Supplement)), 2005. e-Pub 2005.
231. Escalón MP, Saliba RM, Hsu Y, Ghosh S, Ippoliti C, Hosing C, de Lima MJ, Neumann JL, Champlin RE, Couriel DR. Sirolimus in combination with tacrolimus for the treatment of resistant chronic graft-versus-host disease. 2005 ASCO Annual Meeting Proceedings, 2005. e-Pub 2005.
232. Anderlini P, AAcholonu S, Okoroji GJ, Saliba RM, Giralt SA, Ueno NT, Donato ML, Andersson BJ, Champlin RE. Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkin's Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response. Blood 104(11):1654, 2004. e-Pub 2004.
233. Qazilbash MH, Saliba RM, de Lima M, Couriel D, Hosing C, Aleman A, Lei X, Champlin RE, Giralt SA. Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma . Blood 104(11):3329, 2004. e-Pub 2004.
234. Hosing C, Saliba RM, Korbling M, Acholonu S, Karandish S, Giralt S, Lauppe J, de Lima M, Okoroji GJ, Couriel DR, Champlin RE, Khouri IF, Donato ML. Effect of High-Dose Rituximab on Peripheral Blood Stem Cell Mobilization in Intermediate Grade Non-Hodgkin's Lymphomas. Blood 104(11):2877, 2004. e-Pub 2004.
235. Gajewski JL, Saliba RM, Rondon R, Ueno NT, Donato ML, Anderlini P, Korbling M, McMannis JD, Giralt SA, Khouri IK, Mehra R, Champlin RE. High Doses of CD34+ Cells Chemomobilized with G-CSF PBPC Collection Had Greater CD34(+) Cells Collected Than G-CSF Alone and Trended toward Reduced Progression Rate after Autologous PBPC Transplantation for Breast Cancer in a Phase III Trial. Blood 104(11):5235, 2004. e-Pub 2004.
236. Ozdemir E, Saliba RM, Champlin RE, Komanduri KV. A Model to Predict Risk for Late Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation for Hematological Malignancies. Blood 104(11):2241, 2004. e-Pub 2004.
237. Khouri IF, Saliba RM, Couriel DR, Okoroji GJ, Acholonu S, Maadani F, Champlin RE. Effect of Rituximab on the Incidence of GVHD in Lymphoma Patients Who Received the BEAM-Conditioning and an Allogeneic Stem Cell. Blood 104(11):4980, 2004. e-Pub 2004.
238. Khouri IF, Saliba RM, Okoroji GJ, Acholonu S, Maadani F, Hosing C, Champlin RE. Reduced-Intensity Conditioning Regimen with BEAM/Rituximab for Patients with Refractory Non-Hodgkin’s Lymphomas. Blood 104(11):2315, 2004. e-Pub 2004.
239. Khouri IF, Saliba RM, Kebriaei P, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Champlin RE. Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H. Blood 104(11):5132, 2004. e-Pub 2004.
240. Couriel D, Saliba RM, de Lima MJ, Hosing C, Andersson BJ, De Jesus J, Mickler K, Hsu Y, Shpall EJ, Ghosh S, Champlin RE. Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes. Blood 104(11):734, 2004. e-Pub 2004.
241. Anderlini P, Saliba RM, Donato M, Giralt S, Andersson B, Ueno NT, Khouri IF, de Lima M, Ippoliti C, Champlin RE. Allogeneic Stem Cell Transplantation with Reduced-Intensity, Fludarabine-Based Conditioning in Relapsed and Refractory Hodgkin’s Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen on Survival. Blood 104(11):2135, 2004. e-Pub 2004.
242. Gajewski JL, Saliba RM, McMannis JD, Shpall EJ, Ippoliti C, Giralt SA, Jones RB, Khouri IF, Hosing CM, Korbling MJ, Donato ML, Champlin RE. A Pilot Study for Haploidentical Transplant Using a Chemotherapy Only Preparative Regimen with T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts). Blood 104(11):5184, 2004. e-Pub 2004.
243. Khouri IF, Saliba RM, Okoroji GJ, Ippolitti C, et al. Effect of the addition of low-dose alemtuzumab (Campath) in Non-Myeloablative Unrelated hematopoietic transplantation in patients with Lymphoid Malignancies. Blood 102(11):1763, 2003. e-Pub 2003.
244. Khouri IF, Saliba RM, Acholonu A, Okoroji GJ, et al. Improved outcome with high-dose Rituximab (HD_R) with G/GM-CSF and Autologous Stem Cell Transplantation (ASCT) for relapsed aggressive B-CellNon-Hodgkin’s Lymphoma (NHL): The impact of histologies of Follicular (FL) origin. Blood 102(11):2716, 2003. e-Pub 2003.
245. Kloecker G, Saliba RM, Aleman A, Champlin R, Donato M. Higher doses of CD34+ cells are associated with improved disease-free and overall survival after autologous PBSC transplantation for advanced ovarian cancer. Blood 102(11):5656, 2003. e-Pub 2003.
246. Muzaffar QH, Saliba R, Aleman A, Lei X, et al. Risk factors for relapse after CR with high dose therapy for Multiple Myeloma. Blood 102(11):3657, 2003. e-Pub 2003.
247. Couriel DR, Saliba R, Ghosh S, de Lima M, et al. Early Acute GVHD: Syndrome and clinical implications. Blood 102(11):2636, 2003. e-Pub 2003.
248. El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel D, Giralt S, Khouri I, Ippoliti C, Champlin R, de Lima M. Hemorrhagic Cystitis after allogeneic hematopoietic stem cell transplantation: Donor type matters. Blood 102(11):5455, 2003. e-Pub 2003. PMID: 14726405.
249. Donato M, Kurzock R, Champlin R, Saliba RM, et al. Complete remission for late stage Mycosis Fungoides/Sezary syndrome following allogeneic transplantation. Blood 102(11):2702, 2003. e-Pub 2003.
250. Gajewski JL, Cano P, Saliba RM, Giralt SA, Khouri I, Ma Y, Shahjahan M, Couriel DR, Andersson B, Champlin RE. Impact of molecular (mol) HLA typing and anti-thymocyte globulin (ATG) on nonmyeloablative (NMA) unrelated donor bone marrow transplants (BMT). . JCO 22:3360, 2003. e-Pub 2003.
251. Khouri IF, Albitar M, Saliba RM, Ippoliti C, et al. Low-dose (50 mg) Alemtuzumab (campath) in Myeloablative allogeneic stem cell transplantation for CD52+ aggressive hematological malignancies: decreased incidence of acute Graft-versus-Host Disease (aGVHD), with unique pharmacokinetics. Blood 102(11):2658, 2003. e-Pub 2003.
252. Escalon MP, Champlin R, Saliba RM, Acholonu S, et al. Non-Myeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with Non-Hodgkin’s Lymphoma whose disease failed a prior autologous stem cell transplantation (ASCT). . Blood 102(11):255, 2003. e-Pub 2003.
253. Carrasco AA, El-Zimaity M, Saliba R, Shahjahan M, Caldera H, Lee M, Anagnostopoulos A, Andersson B, Khouri I, Giralt S, Champlin RE, de Lima M. Impact of mixed chimerism on the likelihood of disease relapse for patients with AML and MDS. JCO 21:3369, 2003. e-Pub 2003.
254. de Lima M, Saliba RM, Carrasco M, Shahjahan M, et al. Long-term follow up of patients with AML and MDS treated with reduced intensity (RI) or Non-Myeloablative (NMA) conditioning regimens and allogeneic hematopoietic stem cell transplantation (HSCT). . Blood 102(11):2679, 2003. e-Pub 2003.
255. Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gerhenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure (POF) in patients receiving reduced intensity conditioning regimens for hematopoietic stem cell transplantation. JCO 21:3350, 2003. e-Pub 2003.
256. Couriel DR, Carrasco A, Saliba R, Ghosh S, et al. Graft-versus-Host Disease (GVHD) of the liver: a clinicopathological analysis. Blood 102(11):2634, 2003. e-Pub 2003.
257. Donato ML, Saliba RM, Aleman A, Ippoliti C, Gershenson D, Bethancourt D, Champlin RE. Engraftment syndrome in Autologous transplantation: A function of CD 34+ cell dose. Biol Blood Marrow Transplant 9(2):160, 2003. e-Pub 2003.
258. de Lima M, Carrasco A, Lee MS, Saliba R, et al. Mixed chimerism after allogeneic hematopoietic stem cell transplantation (HSCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). . Blood 102(11):2616, 2003. e-Pub 2003.
259. Khouri IF, Lee MS, Saliba RM, Korbling M, et al. Impact of Rituximab on Immunomodulation and survival after Non-Myeloablative allogeneic stem cell transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). Blood 102(11):2690, 2003. e-Pub 2003.
260. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Donato ML, Younes A, Acholonu S, McLaughlin P, Andersson B, Rodriguez MA, Korbling M, Cabanillas F, Champlin RE. Concurrent administration of high-dose Rituximab with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed B-cell lymphomas: Increased efficacy without added toxicity. Blood 100(11):2538, 2002. e-Pub 2002.
261. Khouri IF, Ming-Sheng L, Saliba RM, Jun G, Fayad L, Hosing C, Donato ML, Pro B, Couriel DR, Rodriguez M, Korbling M, Cabanillas F, Ruth K, Champlin RE. Nonablative stem cell transplantation for relapsed mantle cell lymphoma (MCL): a promising strategy for an aggressive disease. Blood 100(11):1652, 2002. e-Pub 2002.
262. De Lima M, Saliba RM, Ma C, Shahjahan M, Giralt S, Donato M, Couriel D, Khouri IF, de Meis E, Andersson BS, Champlin RE, Gajewski JL. Analysis of one Antigen Mismatched Related Transplants for advanced stage Myeloid Leukemias. Blood 100(11), 2002. e-Pub 2002.
263. Khouri IF, Keating MJ, Saliba RM, Ippoliti C, Giralt S, Anderlini P, Gajewski JL, Albitar M, Champlin RE. Mini-dose Campath-1H in-vivo induces significant reduction of GVHD associated with high-dose chemotherapy and allogenic transplantation (ASCT). . Blood 100(11):1639, 2002. e-Pub 2002.
264. Hosing C, de Lima MJ, Saliba RM, Shahjahan M, Couriel DR, Andersson B, Giralt S, Champlin RE. Second allogeneic hematopoietic stem cell transplantation (HSCT) in patients with refractory hematologic malignancies. Blood 100(11):1666, 2002. e-Pub 2002.
265. Mittal P, Saliba RM, Giralt S, Shahjahan M, Cohen A, Karandish S, Champlin RE, de Lima M. Allogeneic transplant for myelofibrosis, CMML and Philadelphia (Ph) chromosome negative/BCR-ABL negative CML (atypical CML): potential survival advantage with reduced intensity regimens. Blood 100(11):1657, 2002. e-Pub 2002.
266. Couriel DR, Hicks K, Saliba RM, Cohen A, Ippoliti C, Donato M, Anderlini P, Giralt S, Khouri IF, Hosing C, de Lima M, Andersson B, Neumann J, Champlin RE. Sirolimus (RAPAMYCIN) for the treatment of steroid-refractory chronic Graft versus Host Disease. Blood 100(11):3344, 2002. e-Pub 2002.
267. Couriel DR, Saliba RM, Hicks K, Cohen A, Ippoliti C, Neumann J, Giralt S, de Lima MJ, Champlin RE. TNF-alpha inhibition for the treatment of Chronic GVHD. Blood 100(11):3343, 2002. e-Pub 2002.
268. Couriel DR, Khouri IF, Anderson B, Cohen A, Saliba R, DeLima M, Martin T, Giralt S, Champlin R. Graft-Versus-Host Disease (GVHD) after non-myeloablative (NMA) versus myeloablative conditioning regimens in fully matched sibling donor hematopoietic stem cell transplants (HSCT): an update. Blood 98(11):1697, 2001. e-Pub 2001.
269. Gajewski J, Khouri I, Champlin RE, Saliba RM, McMannis JD, Donato M, Ueno N, Couriel D, Bibawi S, Shahjahan M, Ma Y, Giralt S. Anti-Thymocyte Globulin (ATG) reduces risk of primary graft failure and may reduce acute graft versus host disease (aGvHD) in 212 Non-myeloablative blood and marrow transplant (BMT) patients (pts) receiving Unrelated or 1 Antign (Ag) mismatched (MM) related donor grafts. Blood 98(11):5311, 2001. e-Pub 2001.
270. Khouri IF, Saliba RM, Lee MS, Giralt S, Younes A, Couriel D, Fayad L, de Lima M, Hagemeister FB, Hosing C, McLaughlin P, Ueno N, Rodriguez MA, Korbling M, Gajewski J, Cabanillas F, Champlin RE. Nonablative allogeneic stem cell transplantation (AST) for Non-Hodgkin’s Lymphoma (NHL): Improved outcome with low incidence of acute GVHD and treatment related mortality. Blood 98(11):1746, 2001. e-Pub 2001.
271. Khouri IF, Saliba RM, Younes A, Acholonu S, Andersson B, Bibawi S, de Lima M, Fayad L, Giralt S, Hagemeister FB, Korbling M, Rodriguez MA, Romaguera J, Cabanillas F, Champlin RE. Allogeneic transplantation for poor risk mantle cell lymphoma (MCL): chemosensitivity predicts superior outcome. Blood 98(11):1745, 2001. e-Pub 2001.
272. Couriel DR, Saliba R, Cohen A, Rondon G, Horton E, DeLima M, Martin T, Ippoliti C, Khouri IF, Gajewski JL, Giralt S, Champlin R. Selection of patients for Antithymocyte Globulin (ATG) treatment in steroid-refractory acute GVHD (SR aGVHD): favorable response in isolated skin or GI involvement. Blood 98(11):5192, 2001. e-Pub 2001.
273. Khouri IF, Saliba RM, Giralt S, Okoroji GJ, Younes A, Fayad L, Korbling M, Rodriguez MA, Couriel D, Bibawi S, Hosing C, McMannis J, Cabanillas F, Champlin RE. Long term remission and low mortality achieved with Cisplatin, Fludarabine, Cytarabine Nonablative Preparative regimen and allogeneic stem cell transplantation (AST) for histologically aggressive Non-Hodgkin’s Lymphoma (NHL). . Blood 98(11):795, 2001. e-Pub 2001.
274. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski J, Mclaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Prolonged failure free survival and molecular responses with nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma. . Blood 98(11):3098, 2001. e-Pub 2001.
275. Gajewski JL, Donato M, Anderlini P, Korbling M, Saliba RM, Rondon G, McMannis JD, Ueno N, Geisler D, Lauppe J, Khouri I, Giralt S, Valero V, Buzdar A, Hortobagyi G, Champlin RE. High doses of CD34+ cells and chemomobilization are both associated with a reduced progression risk after autologus PBSC transplantation for breast cancer in Phase III trial. Blood 98(11):5349, 2001. e-Pub 2001.
276. Donato M, Aleman A, Gershenson D, Wharton JT, Bodurka-Bevers D, Bevers M, Burke T, Levenback C, Wolfe J, Freedman R, Gajewski J, Saliba RM, Champlin R. Results of 102 patients with advanced ovarian cancer treatment with high-dose chemotherapy. JCO 20, 2001. e-Pub 2001.
277. Gajewski J, Saliba RM, Korbling M, Rondon G, McMannis J, Ueno N, Champlin R. High doses of CD34+ cells and chemomobilization are associated with a reduced progression rate after autologus PBSC transplantation for breast cancer. Blood 96:11, 2000. e-Pub 2000.
278. Khouri IF, Giralt S, Saliba RM, Korbling M, Gajewski J, Younes A, Romaguera J, Anderlini P, Rodriguez ML, Donato M, Ippoliti C, Keating M. “Mini”-Allogeneic Stem Cell Transplantation for Relapsed/Refractory Lymphomas with aggressive histologies. JCO 19, 2000. e-Pub 2000.
279. Khouri IF, Saliba RM, Giralt S, Hagemeister F, Korbling M, Younes A, Gajewski J, Ueno N, Andelini P, Cabanillas F, Champlin R. Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy regimens. Blood 96:11, 2000. e-Pub 2000.
280. Gajewski J, Donato M, Anderlini P, Korbling M, Ueno N, Saliba RM, Rondon G, Ippoliti C, Bast R, Buzdar A, Hortobagyi N, Champlin R. Intensive chemotherapy with G-CSF for mobilization yields improved peripheral blood progrnitor (PBPC) collection, quicker recovery after high-dose chemotherapy and reduces progression risk compared to G-CSF alone for mobilization. Proceedings of ASCO 19, 2000. e-Pub 2000.
281. Gajewski J, Rondon G, Mehra, R, Donato, M, Anderlini, P, Korbling, M, Therialt, R, Khouri, I, Giralt, S, Buzdar, A, Ueno, N, Przepiorka, D, Anderson, B, Durrett, A, Saliba RM, J, Molldrem, J, Ippoliti, C, Raber, G, Hortobagi, G, Bast, R, Champlin, R. Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor (GF) for peripheral blood progenitor cell (PBPC) mobilization to growth factor alone for hemapoietic rescue after high dose chemotherapy (HDC). . Blood 92 Suppl 1:10, 1998. e-Pub 1998.
282. Gajewski J, Rondon G, Mirza N, Mehra R, Donato M, Anderlini P, Korbling M, Therialt R, Khouri I, Giralt S, Buzdar A, Ueno N, Przepiorka D, Anderson B, Durrett A, Saliba RM, Bruton J, Ippoliti C, Champlin, R. PBPC improves mobilization and CVP chemotherapy Hematopoietic recovery after autologus PBPC transplant for breast cancer: Preliminary results of a randomized controlled trial. Proceedings of ASCO 17, 1998. e-Pub 1998.
283. Champlin RE, Khouri IF, Saliba R, Cohen A, de Lima M, Giralt S. Dose matters: Improved disease control with increased cytoreduction in Nonablative BMT for Late Chronic or Accelerated Phase CML. Blood 98(11), 1996. e-Pub 1996.